Risk factors and biomarkers for malignant mesothelioma by Panou, Vasiliki
 
  
 
Aalborg Universitet
Risk factors and biomarkers for malignant mesothelioma
Panou, Vasiliki
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Panou, V. (2019). Risk factors and biomarkers for malignant mesothelioma. Aalborg Universitetsforlag. Aalborg
Universitet. Det Sundhedsvidenskabelige Fakultet. Ph.D.-Serien
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 24, 2020
Va
silik
i Pa
n
o
u
R
isk
 Fa
C
To
R
s a
n
D
 B
io
M
a
R
k
ER
s Fo
R
 M
a
liG
n
a
n
T M
Eso
TH
Elio
M
a
Risk FaCToRs anD BioMaRkERs
FoR MaliGnanT MEsoTHElioMa
By
Vasiliki Panou
Dissertation submitteD 2019
1 
 
 
RISK FACTORS AND BIOMARKERS 
FOR MALIGNANT MESOTHELIOMA 
by 
Vasiliki Panou 
 
Dissertation submitted in 2019 
 
. 
  
Dissertation submitted: 08.03.2019
PhD supervisor:  Associate Professor Oluf Dimitri Røe
   Dpts. of Oncology & Clinical Medicine
   Aalborg University Hospital, Denmark
Assistant PhD supervisors: Associate Professor Ulla Møller Weinreich
   Dpts. of Respiratory Diseases & Clinical Medicine
   Aalborg University Hospital, Denmark
   Professor Martin Bøgsted
   Dpts. of Haematology & Clinical Medicine 
   Aalborg University Hospital, Denmark
   Professor Ursula Falkmer
   Dpts. of Oncology & Clinical Medicine 
   Aalborg University Hospital, Denmark
PhD committee:  Clinical Professor Michael Bjørn Petersen (chairman)
   Aalborg University
   Dr.med. Bjørn Hilt
   Norwegian University of Science and Technology
   Clinical Associate Professor Torben Riis Rasmussen
   Aarhus University
PhD Series: Faculty of Medicine, Aalborg University
Department: Department of Clinical Medicine 
ISSN (online): 2246-1302
ISBN (online): 978-87-7210-406-5
Published by:
Aalborg University Press
Langagervej 2
DK – 9220 Aalborg Ø
Phone: +45 99407140
aauf@forlag.aau.dk
forlag.aau.dk
© Copyright: Vasiliki Panou
Printed in Denmark by Rosendahls, 2019
3 
This thesis is based on the following manuscripts: 
 
1. Panou V, Vyberg M, Weinreich UM, Falkmer U, Røe OD. The established 
and future biomarkers of malignant pleural mesothelioma. Cancer Treat 
Rev. 2015;41(6):486-495.  
 
2. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel 
JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Johnson AK, Helgeson 
M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, 
Segal J, Kadri S, Li Z, Kindler HL, and Churpek JE. Frequency of Germline 
Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. 
J Clin Oncol. 2018;36(28):2863-2871. 
 
 
3. Panou V, Vyberg M, Meristoudis C, Hansen J, Bøgsted M, Omland Ø, 
Weinreich UM, Røe OD. Non-occupational exposure to asbestos is the 
main cause of malignant mesothelioma in women in North Jutland, 
Denmark. Scand J Work Environ Health 2019;45(1):82-89. 
 
4. Panou V, Petersen T, Weinreich UM, Vyberg M, Meristoudis C, Hansen J, 
Bøgsted M, Omland Ø, Røe OD. The major role of non-occupational 
asbestos exposure in inducing malignant mesothelioma in Aalborg, 
Denmark. Occupational & Environmental Medicine (submitted). 
 
 
 
RISK FACTORS AND BIOMARKERS FOR MALIGNANT MESOTHELIOMA 
4 
CV 
Born in 1986, Athens, Greece. 
 
Current positions: 
 
2015-2019 PhD student at the Department of Respiratory Diseases,  
Aalborg University Hospital 
2017-present Medical doctor at the Department of Respiratory Diseases,  
Aalborg University Hospital 
2018-present Clinical teacher at Aalborg University 
 
Education: 
2004-2010 Medical doctor, Medical Faculty,  
National & Kapodistrian University, Athens, Greece 
 
Publications 
Original articles 
1. Panou V, Petersen T, Weinreich UM, Vyberg M, Meristoudis C, Hansen J, Bøgsted 
M, Omland Ø, Røe OD. The major role of non-occupational asbestos exposure in 
inducing malignant mesothelioma in Aalborg, Denmark. Occupational & 
Environmental Medicine (submitted). 
2. Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, 
Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, 
Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, 
Kindler HL, King MC, Churpek JE. Inherited Predisposition to Malignant 
5 
Mesothelioma and Survival Following Platinum Chemotherapy. Proceedings of the 
National Academy of Sciences (in press). 
3. Panou V, Vyberg M, Meristoudis C, Hansen J, Bøgsted M, Omland Ø, Weinreich 
UM, Røe OD. Non-occupational exposure to asbestos is the main cause of malignant 
mesothelioma in women in North Jutland, Denmark. Scand J Work Environ Health 
2019;45(1):82-89. 
4. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose 
B, Zhang SR, Weatherly M, Nelakuditi V, Johnson AK, Helgeson M, Fischer D, Desai 
A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler 
HL, and Churpek JE. Frequency of Germline Mutations in Cancer Susceptibility 
Genes in Malignant Mesothelioma. J Clin Oncol 2018;36(28):2863-2871. 
5. Panou V, Vyberg M, Weinreich UM, Falkmer U, Røe OD. The established and 
future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 
2015;41(6):486-495. 
6. Panou V, MD, Jensen PD, MD, Petersen JF, MD, Thomsen LP, MSc BME, 
Weinreich UM, MD. Respiratory Physiological Parameters in Patients with 
Hemoglobin Aalborg. Pulmonary Medicine, Vol. 2014, Article ID 701839, 6 pages. 
Abstracts 
1. Panou V, Weinreich UM, Bibi R, Ravn J, Sørensen JB, Nekrasas V, Santoni ER, 
Røe OD. Predictive biomarkers for malignant pleural mesothelioma. Conference 
abstract presented at Danske Kræftforskningsdage 2018. 
2. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose 
B, Nelakuditi V, Johnson AK, Helgeson M, Fischer D, Sulai N, Turaga K, Huo D, 
Segal J, Kadri S, Li Z, Kindler HL, Churpek JE. Frequency of germline mutations in 
cancer susceptibility genes in malignant mesothelioma. Conference abstract presented 
at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 (Journal 
of Clinical Oncology 36, 2018, suppl; abstr 8564). 
3. Panou V, Meristoudis C, Weinreich UM, Røe OD, Vyberg M. Impact of Calretinin 
immunohistochemistry and the iMig guidelines in the malignant mesothelioma 
diagnosis. Conference abstract presented at the 14th International Mesothelioma 
Interest Group Conference 2018. 
4. Røe OD, Omland Ø, Panou V, Wannag A. Asbestos Consumption, Eternit and 
Pleural Mesothelioma in Norway and Denmark: Similar Populations, Different 
Stories. Conference abstract presented at the 14th International Mesothelioma Interest 
Group Conference 2018 (Best Poster Award). 
RISK FACTORS AND BIOMARKERS FOR MALIGNANT MESOTHELIOMA 
6 
5. Sherman SK, Dahdaleh FS, Panou V, Turaga KM. Second Primary Cancers in 
Patients with Mesothelioma. Conference abstract presented at the 13th International 
Symposium on Regional Cancer Therapy. 
6. Panou V, Vyberg M, Meristoudis C, Omland Ø, Weinreich UM, Hansen J, Røe 
OD.  Malignant mesothelioma in 91 Danish women; The environmental asbestos 
exposure. Conference abstract presented at the American Society of Clinical 
Oncology (ASCO) Annual Meeting 2017 (Journal of Clinical Oncology 35, 2017 
suppl; abstr 8560). 
7. Bak J, Panou V, Weinreich UM, Røe OD.  Malignant mesothelioma in males in 
Northern Jutland, Denmark- incidence, diagnosis and survival. Conference abstract 
presented at the 48th Nordic Lung Congress 2017. 
8. Panou V, Sørensen JB, Nielsen I, Røe OD.  Pemetrexed as first or second line in 
112 danish patients. Conference abstract presented at the American Society of Clinical 
Oncology (ASCO) Annual Meeting 2016 (Journal of Clinical Oncology 34, 2016, 
suppl; abstr e20084). 
9. Panou V, Vyberg M, Meristoudis C, Røe OD.  No BAP-1 cancer syndrome 
associated malignancies detected among 558 Danish patients with malignant 
mesothelioma. Conference abstract presented at the 13th International Mesothelioma 
Interest Group Conference 2016. 
10. Panou V, Omland Ø, Meristoudis C, Hoffmann L, Røe OD. Pleural and peritoneal 
malignant mesothelioma in women correlated to occupational, domestic and 
environmental asbestos exposure. Conference abstract presented at the World 
Conference on Lung Cancer, WCLC/IASLC 2015 (¨Journal of Thoracic Oncology¨, 
2015, Vol 10, Issue 9, Suppl. 2). 
11. Panou V, Omland Ø, Vyberg M, Røe OD. Overrepresentation of malignant 
peritoneal mesothelioma among females in a cohort of 296 Danish patients. 
Conference abstract presented at the 12th International Mesothelioma Interest Group 
Conference 2014. 
12. Panou V, Omland Ø, Langhoff MD, Meristoudis C, Weinreich UM, Røe OD.  
Malignant mesothelioma in women in the region of North Jutland, Denmark; non-
occupational asbestos exposure in more than 50% of the cases. Conference abstract 
presented at the 12th International Mesothelioma Interest Group Conference 2014. 
13. Panou V, Meristoudis C, Røe OD. Malignant mesothelioma in Aalborg, North 
Denmark, Pathology records of the Aalborg University Hospital reveal 562 cases and 
a 13-fold increase in four decades. Conference abstract presented at the 26th European 
Congress of Pathology 2014 (Virchows Archiv, 2014, Vol 465, Issue Suppl 1). 
 
7 
ENGLISH SUMMARY 
 
Malignant Mesothelioma (MM) is an aggressive malignancy with limited therapeutic 
options, firmly associated with asbestos inhalation. It presents typically in the pleura 
(MPM), infrequently in the peritoneum (MPeM), and rarely in pericardium and tunica 
vaginalis. Three major histopathological subtypes are described, epithelioid, 
sarcomatoid and biphasic. Both occupational and non-occupational exposure to 
asbestos can cause MM. However, the latter is under-reported and under-investigated, 
mostly due to the rarity of the disease. It is suspected that cancer susceptibility genes 
are also involved in the MM genesis but their spectrum and prevalence are unknown, 
with the sole exception of the well-described BRCA1–associated protein 1 (BAP1) 
gene. The North Denmark Region in Denmark has an extraordinary high MM 
incidence as a result of two large asbestos emitting industries that operated in its 
capital in densely populated areas and employed more than 25,000 workers for more 
than six decades. This thesis is based on four studies that overall aim to investigate 
risk factors for MM, specifically non-occupational asbestos exposure and genetic 
susceptibility, and to outline the most important current and future MM biomarkers.  
 
The first study summarizes the established and most promising future biomarkers in 
the diagnosis, prognosis and prediction of MPM, emphasizing the need of improved 
biomarkers that can be more helpful in all clinical contexts. The second study 
demonstrates that non-occupational asbestos exposure has had a major impact on the 
men and women of the North Denmark Region, as it is the main cause of MM for 
women and it is implicated in the MM pathogenesis for the majority of the men. The 
study also identifies a ´´hotspot´´, where the population is at higher risk of MM. 
Furthermore, it shows that male and female MM patients have different asbestos 
exposure profiles, with the most common exposure types being domestic and/or 
environmental for the women and occupational and/or environmental for the men. The 
study also indicates that the epithelioid subtype is associated with non-occupational 
and the non-epithelioid with occupational asbestos exposure. Furthermore, MPeM is 
overrepresented among women compared to men and it is more frequent among 
women with occupational versus non-occupational asbestos exposure. The third study 
describes 13 genes with germline mutations in 23/198 MM patients, BAP1, BRCA2, 
CDKN2A, ATM, BRCA1, TP53, MSH6, TMEM127, CHEK2, MRE11A, VHL, WT1, 
and SDHA. Six of these genes are overrepresented in an MM versus a non-cancer 
population (BAP1, BRCA2, CDKN2A, TMEM127, VHL and WT1). Clinical predictors 
of inherited mutation include peritoneal disease, limited asbestos exposure, second 
cancer diagnosis and younger age. Finally, the study unmasked that most of the 
mutated genes are involved in the homologous recombination DNA repair pathway. 
 
In conclusion, this thesis assesses two under-investigated risk factors of MM, genetic 
susceptibility and non-occupational asbestos exposure, and outlines the most 
important MM biomarkers. The thesis provides a framework for future studies. 
RISK FACTORS AND BIOMARKERS FOR MALIGNANT MESOTHELIOMA 
8 
DANSK RESUME 
Malignt mesotheliom (MM) er en aggressiv malignitet, der er stærkt forbundet med 
asbest eksponering. Det forekommer typisk i pleura (MPM) og sjældent i peritoneum 
(MPeM), perikardium og tunica vaginalis. Tre histopatologiske subtyper er beskrevet, 
epithelioid, sarcomatoid og bifasisk. Både erhvervsmæssig og ikke-erhvervsmæssig 
eksponering for asbest kan forårsage MM. Imidlertid er MM som følge af ikke-
erhvervsmæssig asbesteksponering underrapporteret og der er få studier omkring det, 
hovedsagelig på grund af sygdommens sjældenhed. Der mistankes også, at germline 
mutationer er involveret i MM genesen, men deres spektrum og forekomst er ukendte, 
undtaget det velbeskrevne BRCA1–associated protein 1 (BAP1) gen. Region 
Nordjylland i Danmark har en ekstraordinær høj MM-forekomst som følge af to store 
asbestindustrier, der lå centralt i Aalborg og beskæftigede flere end 25.000 arbejdere 
i mere end seks årtier. Denne afhandling er baseret på fire studier, som undersøger 
risikofaktorer for MM, især ikke-erhvervsmæssig asbesteksponering og genetisk 
disposition, og skitserer de vigtigste nuværende og fremtidige MM biomarkører. 
 
Det første studie opsummerer de etablerede og mest lovende fremtidige biomarkører 
i diagnosen og prognosen samt prædiktion af MPM behandlingseffekt. Det andet 
studie viser, at ikke-erhvervsmæssig asbest eksponering har haft stor indflydelse på 
udvikling af MM blandt nordjyske mænd og kvinder, da det er hovedårsagen til MM 
for kvinder, og det er impliceret i MM patogenesen for flertallet af mænd. Studiet 
identificerer også et "hotspot ", hvor befolkningen har større risiko for MM. Desuden 
viser studiet, at mandlige og kvindelige MM patienter har forskellige 
eksponeringsprofiler for asbest; de fleste kvinder har været husstands- og/eller miljø 
udsatte for asbest, mens mænd hovedsageligt har haft erhvervs- og/eller miljømæssig 
asbest eksponering. Endelig indikerer studiet, at epithelioid MM er forbundet med 
ikke-erhvervsmæssig og ikke-epithelioid MM med erhvervsmæssig 
asbesteksponering. Endvidere er MPeM hyppigere forekommende blandt kvinder 
sammenlignet med mænd, og blandt kvinder med erhvervsmæssig versus ikke-
erhvervsmæssig asbesteksponering. Det tredje studie beskriver 13 gener med arvelige 
mutationer hos 23/198 MM patienter (BAP1, BRCA2, CDKN2A, ATM, BRCA1, TP53, 
MSH6, TMEM127, CHEK2, MRE11A, VHL, WT1 og SDHA). Seks af disse gener er 
overrepræsenteret i en MM versus en ikke-kræftpopulation (BAP1, BRCA2, 
CDKN2A, TMEM127, VHL og WT1). Kliniske markører for en arvelig mutation 
indbefatter MPeM, ingen asbesteksponering, anden kræftdiagnose og yngre alder. 
Endelig afslører studiet, at de fleste muterede gener er involveret i DNA reparation, 
den homologe rekombinations-signalvej. 
 
Afslutningsvis omhandler denne afhandling to risikofaktorer for MM, genetisk 
modtagelighed og ikke-erhvervsmæssig asbesteksponering, og beskriver de vigtigste 
MM biomarkører. Endelig sætter resultaterne i denne afhandling ramme for 
fremtidige studier. 
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HMGB1: High-Mobility Group Box 1 
SOMAmers: Slow Off-Rate Modified Aptamers 
DAF: Danish Asbestos Cement Factory 
kg: kilograms 
ADCA: Adenocarcinoma 
CEA: Carcinoembryonic Antigen 
CK5: Cytokeratin 5 
CL4: Claudin-4 
CR: Calretinin 
ER: Estrogen Receptor alpha 
MG: Mammaglobin 
PDP: Podoplanin 
TTF1: Thyroid Transcription Factor-1, 
lncRNA: long non-coding RNA 
SMRP Serum Mesothelin Related Protein 
SD: Standard Deviation 
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IQR: Interquartile Range 
RR: Relative Risk 
CI: Confidence Interval 
OR: Odds Ratio 
ExAC: Exome Aggregation Consortium 
FDR: First Degree Relatives 
SDR: Second Degree Relatives 
HR: Homologous Recombination 
VUS: Variant of Uncertain Significance 
PARPi: Poly(ADP-ribose) polymerase inhibitors 
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CHAPTER 1. BACKGROUND 
Diffuse Malignant Mesothelioma (MM) is a rare and aggressive malignant neoplasm 
caused mainly by asbestos inhalation (1). This neoplasm derives from the mesothelial 
and submesothelial cells of serosal surfaces and presents in the pleura (MPM) in 80-
90% of the cases, in the peritoneum (MPeM) in 10-15% and rarely (less than 1%) in 
the pericardium and tunica vaginalis testis (1–3). There are three histopathological 
MM subtypes, the epithelioid, which is the most common and has the most favorable 
prognosis, the more aggressive sarcomatoid and the biphasic subtype, that consists of 
both sarcomatoid and epithelioid components (3,4). Two subtypes of borderline 
malignant potential have also been identified, the well-differentiated papillary 
mesothelioma and the benign multicystic mesothelioma, which are sporadic and 
mostly develop in the peritoneum (3). The parameters that influence the development 
of the MM subtypes (epitheliod, sarcomatoid or biphasic) and MM location (pleura, 
peritoneum, pericardium or tunica vaginalis testis) are unknown.  
 
1.1. EXPOSURE TO ASBESTOS AND ERIONITE 
Asbestos is a set of six minerals classified in two principal groups, the amphiboles, 
consisting of crocidolite, amosite, tremolite, actinolite and anthophyllite and the 
serpentines that has one compound, chrysotile (5). The amphiboles are characterized 
by straight, longer fibers, while chrysotile is more flexible and has curly, short fibers 
(5)  (Figure 1-1.1) (1). The word asbestos comes from the Greeks and it means 
´´inextinguishable, unquenchable´´, characterizing the material’s fire resistance, 
durability and flexibility (1). Asbestos was used by various cultures since prehistoric 
times; asbestos fibers have been found in debris from settlements from the Stone Age, 
in lamps and candles as early as 4000 B.C., and in Finnish pottery 4,500 years ago 
(1,6,7). Modern asbestos history can be traced around 1850, starting from Canada and 
South Africa (6). The following decades, asbestos mining and manufacturing 
exploded, as manufacturers became fully aware of its desirable physical properties 
and marketed asbestos as the ´´magic mineral´´ (1,6,7). It has since then been used for 
insulation of pipes, buildings, shipbuilding, car brakes, adhesives, and even toys, 
jewelry, textiles, and cigarette filters (1).  
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Figure 1-1.1 Types of asbestos illustrated on election microscopy with energy dispersive X-ray 
spectra (on a 5μm scale). A: Chrysotile, B: Tremolite, C: Crocidolite, D: Amosite, E: 
Anthophylite. Reproduced with permission from Encyclopedia of Occupational Health and 
Safety, Jeanne Mager Stellman, Editor-in-Chief. International Labor Organization, Geneva. © 
2011, ´´Asbestos-Related Diseases´´ by Margaret Becklake. 
 
The direct causal relation between asbestos and MM was first documented in 1960 by 
the South African pathologist John Christopher Wagner, who observed a high 
incidence of this rare malignancy among the workers at the mines of the North-
Western Cape province (8). By the end of the 1960s, there were published more than 
200 reports from several parts of the world, such as the crocidolite mines of Perth and 
the asbestos industries in the United Kingdom and the United States of America 
(USA), identifying asbestos as a carcinogen (6,7). For several years, chrysotile was 
considered to be less carcinogenic than the amphiboles by some scientists, while other 
researchers claimed that chrysotile can only lead to MM when contaminated with 
amphiboles (9,10). Such research has enabled the asbestos industry to keep using 
chrysotile for several decades after it was first linked to MM and other malignancies 
(1). Nonetheless, several animal models and epidemiological studies have concluded 
that chrysotile is an important risk factor for MM and all types of asbestos are declared 
as carcinogens by the World Health Organization and the International Agency for 
Research on Cancer  (1). Asbestos is also an important risk factor for lung cancer and 
the World Health Organization estimates that for every new case of MM, there are six 
asbestos related cases of lung cancer (11,12). Gastric, larynx, colorectal and ovary 
cancer are associated with asbestos inhalation, as well (11). 
Asbestos was banned in most Western countries in the span from 1970-2005, with the 
exception of the USA and Canada, as asbestos is only partly banned in the USA, and 
it was only banned in Canada in 2018 (13,14). In Denmark, asbestos was partly 
0. CHAPTER 1. BACKGROUND 
19 
banned in 1980, further strict restrictions were adopted in 1986 and asbestos was 
completely banned in 1988 (15). However, asbestos use and mining is still to be 
prohibited in developing countries, and worldwide asbestos production is 
approximately 2.2 million metric tons per year, with heavily populated countries 
leading the world mine production (Figure 1-1.2) (16). 
 
Figure 1.1-2.  The biggest asbestos producers worldwide and their asbestos production during 
2010-2017 based on the existing literature (5,6,17–19) 
 
Not only occupational, but also non-occupational exposure to asbestos causes MM. 
Non-occupational exposure includes domestic and environmental exposure, as well 
as exposure to natural occurring asbestos or to commercial asbestos-containing 
materials (1,20–22). Family members that live under the same roof with asbestos 
workers can be exposed to asbestos domestically through the fibers that are 
transported by the laborers on their clothes (23). The extent of the contamination of 
the worker’s clothing is highly dependent on his/hers tasks and the precaution 
measures that are followed, but even low-scale exposure to asbestos can cause MM 
(24). In fact, there is no threshold under which asbestos use is safe, and no linear dose–
response relationship between asbestos exposure and MM (14). Some individuals are, 
though, more susceptible to MM after exposure to asbestos than others, probably 
depending on genetics, the duration of the exposure and the age at first exposure (14).  
Environmental exposure to asbestos is possible via airborne contamination of 
residential areas due to the distribution of asbestos-laden materials and waste products 
from local asbestos plants (25,26). Studies have shown increasing risk of MM with 
decreasing distance from an asbestos plant, with the risk being higher in a 10km radius 
from asbestos industry (20). However, the quantification of the MM risk attributable 
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to non-occupational exposure is challenging and there is limited research on this 
matter (27).  
Despite the ban of asbestos in the Western countries, individuals may still be exposed 
to it due to legacy of past use. Asbestos has been a popular material and as a result 
more than 3,000 products were registered to contain asbestos in the 1970´s (1). The 
linkage between exposure to these profoundly different products and risk of MM is 
difficult to assess. Furthermore, asbestos products are still in place in a large part of 
public and private buildings constructed after the second world war and up to the 90´s 
(5,28,29). The asbestos dust from manipulation of asbestos-containing building 
materials is potentially compromising to the individual’s health, but the personal risk 
for the malignancy is difficult to determine (30,31).  
Naturally occurring asbestos and asbestos-like fibrous minerals can also be 
carcinogenic when found in residential areas and aerosolized due to natural dust 
emissions or anthropogenic activity (22,32). Natural occurring tremolite and 
chrysotile has been identified in villages in Turkey, Greece, Corsica, Cyprus, and New 
Caledonia, fluoroedenite in Sicily, crocidolite in southwestern China and erionite in 
Cappadocia and in the USA (33–38). Erionite is shown to be more potent than 
asbestos in causing MM (39,40). In these areas, the MM incidence rates were found 
to be 100 to 800 times higher than global background rates, the male:female ratio was 
close to one, and age at onset was younger than observed in occupationally exposed 
populations. 
 
1.2. RARE CAUSES OF MALIGNANT MESOTHELIOMA 
Patients that have been exposed to Thorotrast, a radiographic contrast material that 
was used in the 1950´s and atomic energy workers chronically exposed to lower levels 
of radiation are also in high risk for developing MM (41). There are also studies 
describing an association between MM and radiation treatment for Non-Hodgkin 
lymphoma and testicular cancer, as a statistically significant excess of MM was 
identified for these patients (42,43). Simian Virus 40 (SV40) is a DNA tumor virus 
that contaminated some stocks of polio vaccines between 1954-1961 (2). SV40 has 
also been shown to induce MM in animals and it has been implicated in human MM 
tumorigenesis (44). Carbon nanotubes is a family of nanoconstructed materials that 
are being used in electronics, heating elements, batteries and energy storage, fibers 
and fabrics, catalyst supports, air and water purification, dental implants, targeted drug 
delivery, and other medical applications (1). It has been suggested that carbon 
nanotubes can behave like asbestos fibers and induce carcinogenicity (45–47). Future 
research is needed in order to understand their potential role in causing MM and to 
achieve risk control. 
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1.3. EPIDEMIOLOGY 
The incidence of MM varies considerably internationally, and it seems to be 
dependent on the asbestos exposure burden of every country. The incidence is 
increasing and is expected to continue to rise by minimum 5-10% per year until 2025 
in the western countries (40,48). In the USA the incidence of MM is estimated to be 
between 1–2/million in states with minimal and 10–15/million in states with large 
exposure to asbestos (40,49). The age-adjusted MM incidence in Europe during 1994-
2008 has been reported to be 10-30/million, with Italy, United Kingdom and West 
Germany being three of the biggest centers for industrial use of asbestos in the 20th 
century (49,50). There are, though, vast differences in MM incidence, not only among 
the European countries but also within each country´s borders (50). Australia has one 
of the highest global age-standardized incidence rates for MM of 30/million due to 
heavy asbestos industry and asbestos mines that operated for several decades (49,51). 
There are unfortunately few reliable registry data about asbestos exposure and MM 
incidence and mortality from the developing countries. 
MM has a long latency from first exposure to MM diagnosis varying between 20-70 
years (49). Pleural disease has been reported to have longer latency than peritoneal 
(52). MPeM has also been linked to heavier asbestos exposure, both in terms of type 
of asbestos fibers, chrysotile or amphiboles, and type of exposure, occupational and 
non-occupational (53). Researchers have claimed that the attributable risk of MPeM 
is higher as a result of amphiboles compared to chrysotile and occupational versus 
non-occupational asbestos exposure (53). It has also been suggested that the risk of 
MPeM increases remarkably for asbestos workers with high cumulative exposure in 
comparison to MPM (40,53).  However, there are several cases of MPeM attributed 
to chrysotile asbestos and non-occupational exposure in the literature, as well as 
studies that demonstrate that MPeM is more common among individuals with no 
asbestos exposure (40). The above divergent conclusions are a result of the limited 
research of MPeM due to the low incidence rates of the disease worldwide. 
MM is more prevalent in men than women with a 2-5:1 ratio, which has been ascribed 
to their higher degree of occupational exposure to asbestos (40,54). There have been 
studies presenting asbestos exposed female cohorts, e.g. in connection with 
whitewashing of houses in Metsovo, Greece, and in these cases it was the women that 
primarily developed the malignancy (55). Several studies describe a much lower 
percentage of female MM patients with known asbestos exposure in comparison to 
their male counterparts (40). However, it is not clear if non-occupational asbestos 
exposure was taken into consideration in these studies and in which extent. It has also 
been suggested that men and women could develop different phenotypes of MM, as 
female MM patients have a favorable survival compared to men (56). The lack of 
large studies comprising of women with MM challenges the further investigation of 
these matters. Furthermore, MPeM has a weaker causal link to asbestos for women 
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than men, but the mechanisms involved in the MPeM tumorigenesis are not fully 
known (40,53). 
 
1.4. PATHOGENESIS AND MOLECULAR PROFILE 
The most common location for MM development is the pleura. The pleura is a 
membrane that covers the inner surfaces of the chest cavity and consists of a layer of 
mesothelial cells supported by a network of connective and fibroelastic tissue (1). The 
visceral pleura lines the lung, whereas the parietal pleura lines the costae, the 
diaphragm, and the mediastinal structures (Figure 1.4-1) (1). The mesothelial cells 
provide a non-adhesive and protective surface, and they are primarily involved in cell 
and fluid transport across the serosal cavities, but they have also a plethora of 
functions, among others inflammatory responses and phagocytosis of fibers (1). 
Asbestos fibers get transported to the pleura through inhalation, and their shape, 
especially their length/width ratio is important as to the depth of the lung penetration 
(2). There are different pathways, in which asbestos can induce MM. Firstly, asbestos 
fibers cause irritation in the pleura and disrupt the mitotic process, which can lead to 
aneuploidy and chromosome damage typical for MM (2). Asbestos-exposed 
mesothelial cells and macrophages release a variety of cytokines and growth factors, 
which induce inflammation and tumor promotion, including tumor necrosis factor-α, 
interleukin-1β, transforming growth factor-β and platelet-derived growth factor (57). 
Furthermore, asbestos triggers the generation of iron-related reactive oxygen species 
that cause DNA damage and stand breaks (2). Moreover, asbestos induces 
phosphorylation of the mitogen-activated protein kinases and of extracellular signal–
regulated kinases 1 and 2, which increases the expression of early-response proto-
oncogenes in mesothelial cells (2).  
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Figure 1.4-1.  Representation of the normal parietal pleura, the visceral pleura and pleural 
mesothelioma with the most abundant cell types. Reproduced from (1) with permission from 
the publisher. 
 
As a consequence of the above-mentioned mechanisms, cytotoxicity, DNA damage, 
frustrated phagocytosis and chronic inflammation are caused in the pleura and result 
in functional abnormalities conveyed by gene, microRNA and protein expressions. 
Numerous studies have demonstrated that MM has a highly complex and variable 
molecular profile among patients (1,58). Loss-of-heterozygosity investigations have 
demonstrated repeated deletions of distinct sites within chromosome arms 1p, 3p, 6q, 
9p, 13q, 15q and 22q, with the most commonly transformed locations being the tumor 
suppressors CDKN2A–ARF at 9p21, and NF2 at 22q12 (1). Nuclear factor κ-light 
chain enhancer of activated B-cells (NF-κB) is able to act as a survival determinant in 
human mesothelial cells exposed to asbestos fibers (59). Asbestos-induced priming 
and activation of the NLRP3 (nucleotide-binding domain, leucine repeat containing) 
inflammasome initiates an autocrine feedback loop regulated via the interleukin-1 
receptor in mesothelial cells, which is involved in carcinogenesis (60). Members of 
the extracellular signal-regulated kinases family are critical to transformation and 
homeostasis of human epithelioid MM (61). Hepatocyte growth factor and its receptor 
tyrosine kinase, c-Met, are highly expressed in most human MM cell lines (62). 
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BRCA1–associated protein 1 (BAP1) is a tumor suppressor gene located on 
chromosome 3p21 and a member of the ubiquitin C-terminal hydrolase subfamily of 
deubiquitinating enzymes that catalyzes the removal of ubiquitin from protein 
substrates (63). Somatic BAP1 mutations are commonly detected in sporadic MM 
cases, but the reported frequency varies significantly in the literature (22% - 61% of 
the investigated MM specimens), probably due to methodological or ethnical 
dissimilarities (63). 
The underlying mechanisms for the pathogenesis of MPeM are not that well-
documented due to the rarity of the disease, though it is suspected that some of the 
afore-described pathways are similar for MPM and MPeM. Asbestos fibers can 
migrate through an opening in the diaphragm as well as through the lymphatic system 
in sufficient amounts to the peritoneum to cause MPeM, as described in heavily 
exposed populations (40). On the contrary, it has also been suggested that not all cases 
of MPeM are associated with asbestos (64). Chronic inflammation is also considered 
to have a role in the MPeM pathogenesis, as patients with familial Mediterranean fever 
have an increased risk of MPeM (40). Nonetheless, none of these hypotheses has been 
sufficiently documented in the literature. 
 
1.5. GENETIC SUSCEPTIBILITY FOR MALIGNANT 
MESOTHELIOMA 
Genetic susceptibility has long been suspected to increase the risk of MM, as only a 
fraction of the asbestos exposed population develop MM, while there are MM patients 
with no identifiable history of exposure to asbestos or asbestos-like minerals (65). The 
most well-investigated gene in the context of MM pathogenesis is BAP1. Germline 
BAP1 mutations are known to induce an autosomal dominant hereditary cancer 
syndrome, characterized by  high incidence of MM and uveal melanoma, benign 
atypical melanocytic lesions (MBAITs), and by an elevated risk of other 
malignancies, such as cutaneous melanoma, renal cell carcinoma, 
cholangiocarcinoma and basal cell carcinoma (66).  Hereditary BAP1 mutations were 
identified in two families with extraordinary high incidence of MM and in sporadic 
MM cases (67). In addition, it is demonstrated that patients with germline BAP1 
alterations have less aggressive disease and a 7-fold prolonged survival in comparison 
to patients with sporadic MM (68). The exact pathological mechanisms behind the 
genesis of MM and the course of the disease in BAP1 mutation-carriers are not 
distinct. Recent research unveils that there are probably more cancer susceptibility 
genes that can predispose for MM, such as ATM, CDKN2A, BRCA1, BRCA2, MSH6, 
MLH1, PALB2, TMEM127, VHL, WT1, TP53 and others  (65,69–72).  However, the 
prevalence and causative role of germline mutations in MM are not known and no 
standardized gene testing has been included in the guidelines for MM patients and 
their families yet. 
0. CHAPTER 1. BACKGROUND 
25 
 
1.6. CLINICAL PRESENTATION 
The initial symptoms of MPM include chest pain (in 60% of the cases), dyspnea (60%) 
and unilateral pleural effusion, while occasionally patients have no clinical signs (2).  
Constitutional symptoms such as weight loss and fatigue appear later in the course of 
disease and are associated with a worse prognosis (2).  The most common symptoms 
for MPeM include  abdominal distension (73%), abdominal pain (40%), ascites 
(60%), abdominopelvic masses (93%), thrombocytosis (27%), and thromboembolic 
episodes (20%) (40). Palpable subcutaneous masses can present as disease progresses, 
especially after several surgical interventions or thoracocenteses (2). The usual sites 
of spread for MM are the hilar, mediastinal, internal mammary, and supraclavicular 
lymph nodes, together with local invasion in the pericardium, spinal cord and the 
contralateral lung at late  disease stages (2). Distant metastases are uncommon but 
may occur, typically in brain and liver (73,74). 
 
1.7. DIAGNOSIS 
The diagnosis of MM is demanding due to the untypical initial symptoms, the long 
latency, and the challenging histopathological aspects of the disease. 
1.7.1. IMAGING 
Chest radiography is usually the first imaging test to detect abnormalities associated 
with MPM, typically unilateral pleural effusion , diffuse pleural thickening or  focal 
pleural tumors (75). Computed Tomography (CT) is much more sensitive than chest 
radiography and is often an important imaging tool for the diagnosis, staging, and 
treatment follow-up for patients with MPM (76,77). Pleural thickening, pleura 
effusions, enlarged lymph nodes and pulmonary findings, such as nodular metastases 
or lymphangitic carcinomatosis are evident in CT-scans (78). The differentiation 
between benign and malign pleural thickening is crucial (79).  Positron Emission 
Tomography (PET/CT) enhances the accuracy of staging and enables the 
thoracoscopic biopsy from the optimal pleural location (77,80). The majority of the 
MM tumors are 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positive, while the 
FDG uptake is significantly higher in MPM than in benign lesions (Figure 1.7-1) 
(76,81).  
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Figure 1.7-1. Representation of Chest X-ray with right pleural effusion, CT scanning 
with thickening of the right pleura, and PET CT scanning with increased FDG uptake 
in the right pleura in a patient with MPM (A) versus a normal Chest X-ray, CT 
scanning and PET CT scanning (B) (courtesy of Vasiliki Panou). 
 
1.7.2. HISTOPATHOLOGY, CYTOLOGY AND 
IMMUNOHISTOCHEMISTRY 
The gold standard for a MPM biopsy is thoracoscopy, which has a sensitivity over 
90% and risk of complications <10% (82,83). When thoracoscopy is not possible, 
alternative examinations include CT- or ultrasound-guided biopsy with a sensitivity 
of 77-87% and specificity of 100% (82,83). The sensitivity of cytology for the MM 
diagnosis has been reported to vary from 32-76%. The most recent guidelines from 
the International Mesothelioma Interest Group include cytology in the diagnostic 
examinations of choice for MM, but in many countries histological verification is 
required (4,48). For MPeM, laparoscopy is the diagnostic tool of choice (84). 
MM is a challenging histopathological diagnosis to set. The most frequent differential 
diagnosis are lung adenocarcinoma infiltrating pleura and ovarian serous carcinoma 
infiltrating peritoneum. Epithelioid MM may occasionally be difficult to distinguish 
from well differentiated MM, multicystic MM, and benign mesothelial proliferations, 
whereas sarcomatoid MM may be difficult to distinguish from chronic pleuritis and 
from other mesenchymal tumors. The key indicator of MM and other malignancies 
versus benign pleural conditions is the invasion of preexisting tissue, particularly 
adipose tissue, the presence of homozygous deletion of the 9p21 locus encoding the 
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p16/CDKN2A tumor suppressor gene and the immunohistochemically detectable loss 
of BAP1 and MTAP (85–87). The epithelioid and the sarcomatoid subtypes have 
different histopathological patterns, while the biphasic has both epithelioid and 
sarcomatoid components (4). Immunohistochemistry is essential to the MM diagnosis 
(4). The International Mesothelioma Interest Group recommends an 
immunohistochemical panel of two positive (ie, markers frequently expressed in MM) 
and two negative markers (ie, those that are frequently expressed in other relevant 
malignancies but not in MM). (4). Some broadly applied, positive MM markers for 
epithelioid MM are calretinin, cytokeratin 5, D2-40 (podoplanin) and Wilms tumor 
protein-1 (WT1) (Figure 1.7-2). Calretinin is a 29-kd calcium-binding, vitamin D–
dependent protein expressed in more than 90% of epithelioid and biphasic MM, hence 
the most commonly used positive MM marker  (4,88). Cytokeratin 5 is expressed by 
nearly all epithelioid and biphasic MM (89,90). False negative results can be obtained 
when the immunostaining for cytokeratin 5 is done in a small biopsy, but this marker 
has an undeniable utility in differentiating between MM and lung adenocarcinoma 
(4,90). Podoplanin is a mucin-type transmembrane glycoprotein strongly and 
selectively expressed in mesothelial cells and lymphatic endothelium but not in blood 
vessel endothelial cells (91). Podoplanin is particularly useful in distinguishing 
epithelioid MM from lung adenocarcinomas and it is also expressed in 75% of 
sarkomatoid MM (92,93). The Wilms’ tumour (WT) gene, located on chromosome 
11p13, encodes the WT1 (94). WT1 has a great utility in discriminating between 
epithelioid MM from adenocarcinomas or squamous cell carcinomas of the lung (95). 
The most important general “negative” MM markers are epithelial cell adhesion 
molecule (EpCAM) and Claudin 4. EpCAM, (typically detected by the antibody 
clones Ber-EP4 and MOC31) is widely expressed in most carcinomas while only 
occurring focally in 10-20% of MM cases (96). Claudin 4 has approximately the same 
sensitivity as EpCAM with respect to carcinomas and has not been detected in MM 
(97). In the differential diagnosis of MM versus lung adenocarcinoma, thyroid 
transcription factor and Napsin A are highly specific for lung adenocarcinoma and the 
sensitivity is about 80% (95,98). In the differential diagnosis of MM from serous 
ovarian carcinoma, PAX8 and estrogen receptor are highly specific for the latter with 
a sensitivity of about 90% (95,97). 
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Figure 1.7-2. Immunohistochemical staining for malignant mesothelioma with (A) 
calretinin, (B) cytokeratin 5, (C) podoplanin (courtesy of Christos Meristoudis). 
 
1.7.3. STAGING 
The staging classification for MM is problematic, because there is no uniform system 
available. There have been used more than five staging systems, the latest one 
developed by members of the International Mesothelioma Interest Group and the 
Union International Contre le Cancer (99). This recent TNM-based staging system is 
regarded to be the most thoroughly validated of all and is recommended by European 
Respiratory Society and the European Society of Thoracic Surgeons for MPM. 
However, it is far from optimal due to its inaccuracy regarding T- and N-extent, 
especially based on the current imaging techniques (83). There is a consensus about 
the minimal pre-treatment staging assessment and tests for all MM patients that are 
eligible for any kind of active treatment and for combined modality regimes and 
surgery. Among the relevant investigations, mediastinoscopy, video-assisted 
thoracoscopy, endobronchial ultrasound and fine needle aspiration, FDG-PET/CT and 
laparoscopy are important (83).  
 
1.8. TREATMENT 
The MM has an unfavorable prognosis and a median overall survival (OS) of 
approximately 12-16 months for the epithelioid and 4-6 months for the sarcomatoid 
subtype, while less than 5% of the patients survive longer than 5 years (48,100,101). 
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The short survival originates from poor performance score and late stage disease at 
the time of diagnosis, a majority of non-resectable tumors, high perioperative 
mortality and morbidity, chemotherapy and radiotherapy irresponsiveness and 
toxicity to vital organs (48,102). It is crucial to carefully select the right patients that 
are eligible for the right treatment in order to achieve prolonged survival but not 
induce fatal side effects. Unfortunately there are limited prognostic markers for MM. 
Non-epithelioid subtype, pleural disease, performance status higher than 0, lactate 
dehydrogenase >500 IU/L, platelet count >400,000/µL, male gender and age >75 
years are identified as independent predictors of poor outcome (48). MM management 
is more effective when a multidisciplinary team of pulmonologists, oncologists, 
radiologists, surgeons and pathologies assesses the patients. The typical treatment 
options include chemotherapy, surgery and radiation, while treatment for MPM and 
MPeM differ essentially (see 1.8.4). 
 
1.8.1. CHEMOTHERAPY 
Chemotherapy is most commonly administrated either for palliative purposes or as 
neo-adjuvant therapy prior to surgery. Since 2003, the standard of care chemotherapy 
for MPM is a combination therapy with cisplatin and pemetrexed with 
supplementation of B12 vitamin and folic acid, as it was proven to significantly 
increase the OS from 7-9 to 12 months in a randomized phase III study (100). The 
combinations of carboplatin and pemetrexed or cisplatin and gemcitabine are good 
alternatives for MPM patients who cannot receive cisplatin and pemetrexed, 
respectively (48). No single-agent chemotherapeutic and non-platinum-based 
polychemotherapies have shown to increase the OS for MM in the context of first-
line therapy and no single-agent or polychemotherapies are proven to be efficient as 
second-line farmaka (83,103). A second-line option with reasonable response rate and 
acceptable toxicity is vinorelbine, while bevacizumab is a promising agent, as well 
(104–107). One of the biggest challenges for the MPM treatment is that a significant 
part of the patients will not respond to chemotherapy, as one of MPM characteristics 
is the high rate of innate and acquired chemoresistance (108). 
 
1.8.2. SURGERY 
Selected patients may be eligible for surgery with curative intent, but surgery has not 
been shown to increase survival in a randomized trial (109,110). The aim of curative 
intended surgery is to resect all visible tumor but micro-residual disease cannot be 
avoided and therefore, surgery is always combined with chemotherapy (48). There are 
two main types of surgery, extra-pleural pneumonectomy (EPP) and 
pleurectomy/decortication (P/D). In EPP the surgeon removes en bloc the visceral and 
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parietal pleurae, the lung, the ipsilateral hemidiaphragm, and the adjacent pericardium 
(111). P/D is defined as parietal and visceral pleurectomy without resection of the 
diaphragm or pericardium. There is also the extended P/D, where the diaphragm 
and/or pericardium are removed, and the partial pleurectomy, where there is no 
complete tumor resection but partial removal of parietal and/or visceral pleura for 
diagnosis or palliation (111). There is no international consensus on which surgical 
procedure is more beneficial for the MPM patients, EPP or (extended) P/D (109,111). 
There is complete agreement, though, that the patients that are eventual candidates for 
surgery require appropriate staging, cardiac and pulmonary evaluation prior to the 
surgical procedure. Patients with mediastinal lymph nodes, metastases, poor 
performance status and non-epithelioid histology are not eligible for surgery (48).  
 
1.8.3. TREATMENT OF MALIGNANT PERITONEAL MESOTHELIOMA 
Initially, MPeM patients received the same polychemotherapy with pemetrexed and 
cisplatin, as MPM patients, with similar or slightly better results (OS of 10 - 26.8 
months) (112). Nowadays, systematic chemotherapy is reserved for patients that are 
not candidates for radical treatment (84). Radical treatment consists of cytoreductive 
surgery combined with perioperative hyperthermic intraperitoneal chemotherapy 
(HIPEC), and has been used for almost a decade (112). There are no standardized 
chemotherapeutic agents used in HIPEC (84). The chemotherapeutics are 
administrated at a temperature of 40.5- 43 °C in the peritoneal cavity after the end of 
the cytoreductive surgery, with or without early postoperative intraperitoneal 
chemotherapy (84). In this way, a higher concentration of cytotoxic drugs at tumor 
bearing sites is achieved and lower systemic side effects are observed in comparison 
to the systematic chemotherapy (84). The overall 5-year survival rate is reported to be 
between 29% – 63%, while mortality and morbidity rates vary significantly in various 
studies, as well (mortality rate of 0% - 20%, and morbidity rate of 8.3% - 90% with 
half of the studies reporting morbidity between 40% - 65%) (112). Hyperthermic 
intrathoraric chemotherapy has also been investigated for MPM but is of limited 
utility due to the risk of serious side effects (113). 
 
1.8.4. RADIATION THERAPY 
Radiation therapy can be used in the setting of palliative care for the management of 
chest wall pain and subcutaneous tumor spread, and as part of a multimodal approach 
(75,83). Prophylactic radiation after thoracocentesis does not seem to prevent 
subcutaneous metastases along the drainage canals and it is therefore not 
recommended (83). Adjuvant and neoadjuvant radiation in the context of a 
multimodal treatment was initially found to decrease the rate of local recurrence after 
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EPP (114,115). In more recent studies, hemithoracic prophylactic radiation after 
surgery was not associated with longer relapse-free survival, but with fatal pulmonary 
toxicity (116,117). Currently, radiation therapy is not a standardized part of the 
multimodality approach, but its use in MPM centers around the world after surgery is 
not uncommon. 
 
1.8.5. EMERGING THERAPEUTIC OPTIONS 
There is a number of clinical studies and trials investigating potential agents for the 
treatment of MM, including Epidermal growth factor receptor (EGFR) inhibitors, 
antibody conjugated toxins, immune checkpoint inhibitors, gene-based therapies and 
tumor vaccines (118). A promising future treatment could be immunotherapy. 
Programmed death receptor is found on the surface of T-cells and, when activated by 
a programmed death ligand 1 (PD-L1), it leads to cell death (119). PD-L1 is expressed 
in 20%-40% of MPM patients, mainly in non-epithelioid subtypes, while higher 
expression is correlated with worse prognosis (4.8- 5 versus 14.5-16.3 months) (120). 
Monoclonal antibodies against PD-L1 are being used in clinical trials for patients with 
locally advanced or metastatic MM, who did not respond or were unable to receive 
standard chemotherapy (118,121). The preliminary results show, that the agent is 
well-tolerated, while the majority of the patients presented partial response or stable 
disease and a median OS of 11.5 months (118,121,122). Photodynamic therapy, 
iodine-povidone (betadine) lavage and cryotherapy have also shown encouraging 
results but the available studies have yet to provide convincing evidence of efficacy 
(123–125). 
 
1.9. BIOMARKERS FOR MALIGNANT MESOTHELIOMA 
Numerous studies have attempted to identify molecular biomarkers that may have a 
role in diagnosis, screening, prognosis and prediction for MM but none is found to be 
robust enough to be adopted in clinical practice. Currently, the most promising MM 
biomarker is mesothelin (126,127). Mesothelin is a cell surface glycoprotein that is 
expressed on MM, ovarian, pancreatic, and other malignancies, while its expression 
on normal tissues is limited (128). It can be detected in tumor cells and in blood (128). 
Mesothelin can serve as a diagnostic biomarker, as it is elevated in the serum, pleural 
effusion and ascites of MM patients versus non-cancer population and an assay for its 
quantification in serum has been commercialized (MESOMARK ®) (129–131).  
Other interesting biomarkers for MM are osteopontin, fibulin-3, high-mobility group 
box 1 (HMGB1), hyaluronic acid, micro-RNA, and proteomics  (126,127). 
Osteopontin is an extracellular cell adhesion protein that is up-regulated in asbestos-
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exposed rats and cells in vitro, while serum osteopontin levels were found to be 
significantly higher in patients with MPM than in a non-malignant asbestos-exposed 
population (132). Fibulin-3 is an extracellular glycoprotein encoded by the epidermal 
growth factor gene, and it is reported to be significantly elevated in plasma and pleural 
effusion of MPM patients versus asbestos-exposed individuals (133). Asbestos 
exposure induces necrosis of human mesothelial cells, and results in the release of 
HMGB-1 that is an inflammation mediator (134). Higher serum HMGB1 level is 
detected in MPM patients versus asbestos-exposed and healthy controls, suggesting 
HMGB1 as a potential diagnostic marker for MPM (134). Hyaluronic acid was found 
elevated in MM pleural effusions in the 1980s but follow-up studies were limited due 
to technical restrictions (135). After the development of modern assays, hyaluronic 
acid in pleural effusions has demonstrated similar diagnostic accuracy to mesothelin, 
while the accuracy improves by the combination of the two markers (136,137). 
Micro-RNAs are a family of small non-coding RNAs that negatively regulate gene 
expression by inhibiting the translation of target messenger RNA (138). Several 
micro-RNAs, including micro-RNA-197-3p, micro-RNA-1281, micro-RNA-126, 
micro-RNA--625-3p and micro-RNA 32-3p, have been found elevated in MPM 
patients comparing to control groups (139–141). Micro-RNA-29 in MM was 
increased in serum of patients with epithelioid histology, and it was associated with 
more favorable prognosis (142). A group of six micro-RNAs has been documented to 
be of prognostic value for MPM patients, who have undergone EPP (143). Slow Off-
Rate Modified Aptamers (SOMAmers) are short, single stranded deoxynucleotides 
with the ability to function as capture reagents (144). By the use of SOMAmer 
technology, a candidate 13 biomarker panel, consisting of novel inflammatory and 
proliferative proteins, was developed for the detection of MPM in asbestos-exposed 
individuals (144). Its sensitivity ranged from 77% to 96% depending on the disease 
stage (sensitivity of 77% for stage I, 93% for stage II and 96% of stage III-IV) (144). 
 
1.10. ASBESTOS AND MALIGANT MESOTHELIOMA IN THE 
REGION OF NORTH DENMARK 
The Region of North Denmark has had a high incidence of MPM compared to the rest 
of Denmark for more than three decades (data from the NORDCAN database). The 
crude and age-standardized rate of MPM for the North Denmark Region has been 
higher since 1980 and almost double as high since the late 1990´s compared to the 
rest of Denmark (Figure 1.9-1, Appendix A). The highest age-standardized rates were 
observed in 2011 (7.3/100,000), 1999 (7.2/100,000), 2006 (7.0/100,000), 2015 
(6.6/100,000) and 2010 (6.5/100,000), but the top is yet to be reached. Data about the 
incidence of MPeM are not available.  
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Figure 1-9.1.  Representation of the age-standardized rate for Malignant Pleural Mesothelioma 
for the Region of North Denmark and Denmark during 1972-2015 (based on data from 
NORDCAN, http://www-dep.iarc.fr/NORDCAN/English/frame.asp). 
 
The high incidence is associated to the asbestos industry that has operated in the area. 
The only Danish Asbestos Cement Factory (DAF) was located centrally in the city of 
Aalborg, the Region’s capital, neighboring with numerous residencies and four 
schools. DAF was founded in September 1927, while the manufacture of its principal 
product, asbestos cement sheeting, was initiated in April 1928 (historical data from 
Aalborg Archive). Chrysotile asbestos was mainly used, with the exception of the 
period 1946-1968, where small amounts of amosite (10%) and crocidolite (1%)  were 
also utilized (145). From 1928-1933 asbestos was imported from Russia, Canada and 
Rhodesia but since 1935, the company’s primary supplier was the Amiandos mine 
located at the mountain Troodos in Cyprus (historical data from Aalborg Archive). 
The asbestos import varied throughout the years, it started from 17,000-25,000 kg in 
1928 and peaked in the 1970s with approximately 25,000-34,000 metric tons annually 
((146), historical data from Aalborg Archive). The Danish asbestos import was quite 
high in comparison to the Scandinavian countries, e.g. higher compared to Norway 
and Sweden, and this is reflected in the high MM incidence, especially in the Region 
of North Denmark (Figure 1-9.2, (147)). A total of 8,000 men and 590 women were 
working at DAF before asbestos was banned (146).  
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Figure 1-9.2.  Representation of the use of asbestos (forbrug) in tons (t) during 1940-2000 and 
the incidence of Malignant Mesothelioma (MM) in Denmark and Norway. Orange line: MM 
incidence for men in Denmark, Green line: MM incidence for women in Denmark, Blue line: 
MM incidence for men in the Region of North Denmark, Yellow line: MM incidence for women 
in the Region of North Denmark, Grey line: MM incidence for men in Norway, Purple line: 
MM incidence for women in Norway, Red bold line: Asbestos import in Denmark, Grey bold 
line: Asbestos import in Norway. Reproduced from Ugeskr Læger 2018;180:V02180128 with 
permission from the publisher and Oluf D. Røe. 
 
Asbestos was officially banned in Denmark in 1980 but dispensation was given for 
manufacturing of brake blocks and asbestos cement products, which was the principal 
product of DAF, thus the production line was not affected initially (historical data 
from Aalborg Archive).  In 1986 a stricter regulation was voted by the parliament, 
banning construction of all kind of asbestos-containing products and only allowing 
the use of asbestos in brake blocks, which was further prohibited in 1988 (historical 
data from Aalborg Archive). The Amiantos mine was donated in 1986 to the Bishop 
of Limassol and asbestos mining was terminated in 1988 (historical data from Aalborg 
Archive). A large shipyard was also based in Aalborg, which was established in 1912 
and closed in 1988. There is no consistent information about the exact total number 
of employees at Aalborg Shipyard during 1912-1988, but it is estimated to be between 
15,000-25,000 individuals (Figure 1-9-3). Another big shipyard operated in the city 
of Frederikshavn from 1870-1999 (historical data from Aalborg Archive). Crocidolite 
asbestos was mainly used in both shipyards.  
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Figure 1-9.3.  Representation of the approximate number of employees at Aalborg Shipyard 
during 1912-1988 (data from Aalborg Archive and from the book ‘’Byens Værft’’ by Flemming 
Nielsen. 
 
As a result, an extensive number of the residents of the Region of North Denmark, 
and particularly of Aalborg, have been exposed to asbestos through either their job, 
or the environment or their household members that were asbestos workers. The 
studies about asbestos exposure and its impact on the affected population in Aalborg 
and the Region of North Denmark are scarce. One study from 1989, investigated the 
incidence of cancer and mortality among 8580 male and female workers at DAF 
between 1928 and 1984 and showed increased overall mortality, cancer mortality and 
overall incidence of cancer in men, compared to the Danish male population; the 
equivalent was not seen in women (146). A subsequent study by the same author 
examined the histological patterns of the lung cancer cases for this population, 
confirming a link between lung adenocarcinoma and asbestos (145). A recent study 
explored the risk of MM in children who attended a school near DAF and concluded 
that they had a significantly higher risk of MM as adults (148). No large studies have 
been conducted previously to investigate the effect of occupational and non-
occupational asbestos exposure on the total population of North Denmark and its 
causal relationship with MM.   
To summarize, the high historical asbestos burden of Aalborg culminated in a 
particularly high and increasing MM incidence for the Region of North Denmark. 
This resulted in hundreds of male and female patients diagnosed with MPM and 
MPeM through the last decades, a man-made epidemic. For all these patients, there 
are available data, with clinical, pathological and asbestos exposure information 
through the medical records and the high-quality Danish registries. Thus, through 
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these unique and validated repositories, large studies on male and female populations 
with MM can be performed.
37 
CHAPTER 2. AIMS OF THE THESIS 
As illustrated in Chapter 1, there is a plethora of studies examining biomarkers for the 
diagnosis, prognosis and prediction of MM but their clinical utility is highly limited. 
Furthermore,  non-occupational asbestos exposure and genetic susceptibility are two 
under-investigated subjects in the context of MM carcinogenesis, mostly due to the 
sparse studies on large populations, consisting of both men and women. Therefore, 
this thesis hypothesizes that: 
i. The reports about the sensitivity and specificity of the established and 
emerging diagnostic, prognostic and predictive MPM biomarkers differ to a 
large extent and this hinders their clinical utility. 
ii. Non-occupational asbestos exposure has a significant role in the 
tumorigenesis of MM. 
iii. The asbestos exposure profiles for men and women with MM present with 
considerable dissimilarities. 
iv. The asbestos exposure pattern and the patient´s gender can influence the 
location of the MM development and the histopathological MM subtype. 
v. Inherited mutations other than in the BAP1 gene are implicated in the MM 
genesis and germline mutation carriers share common clinical 
characteristics. 
The study aims are to: 
1. Summarize the most important current and most promising future biomarkers 
within the diagnosis, prognosis and prediction for MPM.  
2. Explore the extent and impact of non-occupational asbestos exposure for women 
and men with MM.  
3. Elucidate and compare the asbestos exposure patterns for the male and the female 
MM patients. 
4. Examine whether the histopathological MM subtype (epithelioid or non-
epithelioid) and the MM location (pleura or peritoneum) are associated with the 
type of asbestos exposure or the gender of the patient. 
5. Assess the prevalence and the spectrum of germline mutations in MM.  
6. Determine disease characteristics that can predict the presence of a germline 
mutation. 
7. Explore genetic pathways in MM carcinogenesis. 
Three studies were planned and performed in order to investigate the above-
mentioned aims, a literature review, a retrospective, observational study and a 
prospective study (Figure 2-1.1). The literature review (Study I) discusses established 
and emerging MPM biomarkers with current or potential clinical impact in diagnosis, 
prognosis and prediction (Aim 1). The retrospective, observational study (Study II) 
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explores the role of non-occupational asbestos exposure in women (Study IIa) and 
men (Study IIb) with MM (Aims 2, 3 and 4). The prospective study (Study III) 
examines the prevalence, spectrum and clinical predictors of germline mutations in 
cancer susceptibility genes in MM (Aims 5, 6 and 7). The four papers will from heron 
be referred to as named above. 
 
 
Figure 2-1.1. Overview of studies included in this thesis and titles of corresponding papers. 
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CHAPTER 3. PRESENTATION OF THE 
STUDIES 
The principal methods and main findings of the Studies I, II and III will be outlined in 
this chapter. For further details, please refer to the manuscripts. 
 
3.1. STUDY I 
 
3.1.1. MATERIALS AND METHODS 
A literature research without a lower data limit was conducted on the databases 
PubMed and PLOS ONE by using the following keywords: “malignant 
mesothelioma” and “biomarkers”, “immunohistochemistry”, “BAP-1”, 
“deformability cytometry”, ‘’fibulin-3”, “genome profile”, ‘’hyaluronan’’, “long non-
coding RNA”, “mesothelin”, “microRNA”, “osteopontin”, “proteomics”, “soluble 
mesothelin related protein’’. The reference lists of relevant publications were utilized, 
as well. Articles written in English and published until April 26th, 2015 were reviewed.  
 
3.1.2. RESULTS 
The search revealed contradicting studies about diagnostic, prognostic and predictive 
biomarkers for MM. Markers that are currently in clinical use or present with a 
potential for MM are presented in this review. Immunohistochemistry is the 
cornerstone of the MPM diagnosis. There are no single immunohistochemical markers 
that are sensitive and specific enough to set the diagnosis, especially for sarkomatoid 
MM. Thus, a panel of two immunohistopositive and two immunohistonegative 
markers has been included in the guidelines for the MPM diagnosis since 2009. 
Calretinin, cytokeratin 5, podoplanin and WT1 are among the most important 
immunohistopositive diagnostic markers for MM. Carcinoembryonic antigen, 
Claudin-4, epithelial cell adhesion molecule, thyroid transcription factor estrogen 
receptor and mammaglobin are some of the most useful immunohistochemical MM 
markers (Table 3-1.1). Mesothelin in serum and pleural fluid is the most promising 
diagnostic marker for MM and the only approved marker for the monitoring of non-
sarcomatoid MPM by Food and Drug Administration. Osteopontin, hyaluronate, 
fibulin-3, deformability cytometry, selected reaction monitoring assay technology, 
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fluorescence in situ hybridization assay and microRNA present with a certain interest 
among the MM biomarkers in serum, plasma and pleural fluid, as well (Table 3-1.2). 
Long non-coding RNA, proteomics and gene expression profiling are emerging 
biomarkers for the MM diagnosis and prognosis, while BAP1 is the most robust MM 
susceptibility marker (Table 3-1.2). There are no validated predictive MPM 
biomarkers yet, but in studies, thymidylate synthase, excision repair cross-
complementation group 1 and BAP1 have shown some potential in predicting survival 
and response after pemetrexed and vinorelbine-cisplatin chemotherapy. 
 
Tumor Mesothelioma markers Broad spectrum 
carcinoma markers 
Lung 
ADCA 
marker 
Breast 
ADCA 
markers  CR CK5 PDP WT
1 
CE
A 
CL
4 
EpCA
M 
TTF1 ER M
G 
MM 
epitheli
oid 
+ +/- + +/- -(+)f - -/+f - - - 
Lung 
ADCA 
-/+f -/+f -
(+)f 
- +/- + + +/- -/+ -
(+)f 
Breast 
ADCA 
-/+b -/+b -/+ -/+ +/- + + -(+)f +/- +/- 
 
+     : >90% positive 
+/-  : 50-90% positive 
 -/+ : 10-<50% positive   
-(+) : 1-<10% positive  
 -      : <1% positive  
f: focal when positive  
b: basal-like type in most cases when positive 
ADCA: adenocarcinoma, CEA: carcinoembryonic antigen, CK5: cytokeratin 5, CL4: Claudin-
4, CR: calretinin, EpCAM: epithelial cell adhesion molecule, ER: estrogen receptor alpha, MG: 
Mammaglobin, MM: malignant mesothelioma, PDP: podoplanin, TTF1: thyroid transcription 
factor-1, WT1: Wilms' tumour-1 (nuclear reaction) 
Table 3-1.1. Commonly used markers and their expression pattern in the immunohistochemical 
classification of epithelioid malignant mesothelioma versus lung and breast adenocarcinoma. 
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Biomarker Location Sensitivity Specificity 
Mesothelin/SMRP Serum, pleural 
effusion 
68 - 90% 80 - 95% 
Osteopontin Serum, plasma,  
body fluids, tissue 
58 - 95% 53 - 95% 
Fibulin-3 Plasma, pleural 
effusion 
22 - 94% 71 - 100% 
Hyaluronate Pleural effusion, 
serum 
50 - 56% 98 - 100% 
MicroRNA Tissue, plasma 63 - 100% 74 - 95% 
SOMAmers Plasma 77 - 96% 91 - 95% 
lncRNA Tissue 71% 100% 
Gene expression 
 ratio test 
Tissue 100% 90% 
lncRNA: long non-coding RNA 
SOMAmers: Slow Off-rate Modified Aptamers 
SMRP: Serum Mesothelin Related Protein 
 
Table 3-1.2. Selection of potential diagnostic mesothelioma biomarkers, their location, 
sensitivity and specificity, as reported in several studies. 
 
3.1.3. CONCLUSION 
This study managed to outline the established and future diagnostic, prognostic and 
predictive biomarkers for MM (Aim 1). The gold standard of MM diagnosis is 
immunohistochemistry. Due to the difficulty of establishing the diagnosis, the 
International Mesothelioma Interest Group introduced guidelines with two positive 
and two negative markers to increase sensitivity and specificity. Serum and pleural 
fluid mesothelin is the only approved circulating biomarker for diagnosis and 
monitoring of treatment. New markers are constantly emerging, such as BAP1. 
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3.2. STUDY II  
 
3.2.1. MATERIALS AND METHODS 
3.2.1.1 Study Population 
Histological and cytological samples from MPM and MPeM that were stored in the 
archives of the Institute of Pathology during 1970-2015 were considered for inclusion 
in the study. All the samples were reclassified by two experienced pathologists 
individually to verify the diagnosis. The reclassification was based on a 5-tiered 
scheme with the following categories: 1. Definitely MM, 2. Probably MM, 3. Likely 
MM, 4. Unlikely MM and 5. Definitely not MM. Additional immunostainings 
according to the International Mesothelioma Interest Group guidelines were applied, 
when necessary. Biopsies classified as ‘definitely’, ‘probably’ and ‘likely’ MM were 
included at the study. All the included patients had an additional clinical diagnosis of 
MPM or MPeM, and if this was not the case, they were excluded from the study.  
3.2.1.2 Data Sources and Recovery 
Information about asbestos exposure, MM characteristics and patient survival were 
acquired from a plethora of sources. The Danish Supplementary Pension Fund 
Registry, the Danish Civil Registration System and the patients’ medical records 
(assessments from lung specialists and occupational health specialists in particular) 
provided information about asbestos exposure. The MM subtype, epithelioid or non-
epithelioid (including sarcomatoid and biphasic) and the MM location, pleura or 
peritoneum, were registered through the archives of the Institute of Pathology and the 
Danish Cancer Registry. A unique personal identification number allowed us to 
combine data from all the above registries for each patient. The Nordic Cancer 
database, NORDCAN and Statistics Denmark were also used. 
3.2.1.3 Asbestos Exposure 
Potential asbestos exposure was categorized in three main groups, occupational, non-
occupational and unknown exposure, and combinations of those (Figure 3-2.1). 
Occupational asbestos exposure characterized the asbestos workers. Non-
occupational asbestos exposure included domestic exposure, for patients sharing 
residence with asbestos workers and environmental exposure, for people living or 
working within 10km of an asbestos plant. The choice of the 10km radius was based 
on previous studies. All patients that had worked with asbestos were placed in the 
‘Occupational exposure’ group, regardless if they were also exposed to asbestos non-
occupationally. Patients with domestic and/or environmental exposure were allocated 
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to the ‘Non-occupational exposure’ group. The ‘Unknown exposure’ category was 
used for the cases, where no asbestos exposure could be identified. 
 
Figure 3-2.1. Categorisation of asbestos exposure. 
 
3.2.1.4 Statistical Analysis 
The population demographics were characterized by descriptive statistics. Categorical 
data were presented as total number (frequency/%) and continuous data as either mean 
(standard deviation (SD)) or median (interquartile range (IQR)) depending on normal 
distribution, evaluated by the Shapiro-Wilk test. Two-sided Fisher´s exact and 
Pearson’s chi-square test were used to test differences between two groups of 
categorical variables, and logistic regression to correlate a dependent with two 
independent categorical variables. The independent t-test or the Wilcoxon signed-rank 
test was applied to test the means of normally or not-normally distributed groups, 
respectively. Statistical significance was reached when p < 0.05.  
Study IIa 
For the study IIa, the cumulative incidence and the spatial relative risk (RR) of MM 
among women that resided the parishes of the North Denmark region during 1974–
2015 was determined. The median number of female residents for every five-year 
period during 1980-2015 was registered in order to assess the number of women at 
risk in each parish and in Denmark. Henceforth, the ratio of the number of the 
cumulated MM cases and the estimated number of female residents at risk, divided by 
41 years of observation was used to calculate the cumulative incidence of MM per 
100,000 residents in the period 1974–2015 for each parish and Denmark. By dividing 
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the cumulative incidence of the parish with the total cumulative incidence of 
Denmark, the RR over the period 1974–2015 for each parish was obtained.  
Study IIb 
For the study IIb, the cumulative incidence of occupational and non-occupational MM 
cases during 1970-2015 for the male residents of the parishes of the Region of North 
Denmark was determined. An estimation of the number of men at risk in each parish 
was calculated using the median number of male residents for every five-year period 
during 1980-2015. The cumulative incidence of MM was computed by the ratio of the 
number of cumulative MM and the estimate of men at risk divided by 46 years of 
observation per 100,000 residents. The cumulative MM incidence for all the MM 
cases of each parish was divided with the cumulative incidence of Denmark in order 
to find the RR of MM for the male residents of the North Denmark Region compared 
to the Danish men. 
For both Study IIa and Study IIb, the 95% Confidence Intervals (CI) were calculated 
by the Clopper-Pearson’s method. No age adjustment was made due to lacking 
information about the age distribution in the parishes and in Denmark. 
 
3.2.2. RESULTS 
3.2.2.1 Population Demographics 
Out of 575 patients with MPM and MPeM from the archives of the Institute of 
Pathology, Aalborg University Hospital, 427 were included in the study, hereof 91 
women and 336 men (male:female ratio of 3.7:1) (Figure 3-2.2). The population 
characteristics are summarized in Table 3-2.1.  
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Figure 3-2.2. Inclusion flowchart for Study II. 
 
 
Total number of patients, N (%) 427 (100%) 
Gender, N (%)  
  Men 336 (79%) 
  Women 91 (21%) 
Disease topography, N (%)  
  Pleura 382 (90%) 
  Peritoneum 45 (10%) 
Disease subtype, N (%)  
  Epithelioid 260 (61%) 
  Non-epithelioid 144 (34%) 
  Unknown 23 (5%) 
Age at diagnosis, mean (SD) 67.6 (10.7) 
Age at first exposure, median (IQR) 1 (22) 
Exposure duration- environmental, median (IQR) 55 (17) 
Exposure duration- occupational, median (IQR) 23 (22) 
Exposure latency, median (IQR) 60 (28) 
 
Table 3-2.1. Patient demographics. 
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3.2.2.2 Malignant Mesothelioma in the North Denmark Region 
The crude incidence of MM for the men and women of the North Denmark Region is 
particularly high and still increasing (Figure 3-2.3). Especially the women of the 
Region of North Denmark have 1.9-2.6 higher risk of developing MPM in comparison 
to the women of the other Danish regions (Table 3-2.2). 
 
 
Figure 3-2.3. Crude incidence rate for malignant mesothelioma (MM) for the women (black 
color) and both men and women (grey color) of the Region of North Denmark, Denmark. 
 
 
 
Danish Regions Crude rate Relative risk ratio 
North Denmark/other Danish 
Regions 
North Denmark 1.3 - 
Central Denmark 0.7 1.9 
South Denmark 0.7 1.9 
Capital 0.6 2.2 
Zealand 0.5 2.6 
 
Table 3-2.2. Malignant mesothelioma incidence per 100,000 inhabitants in Danish regions and 
relative risk ratio as to the Region of North Denmark during 2010-2014. Data from Nordcan 
and the Danish Cancer Registry. 
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Study IIa 
A map over the Region of North Denmark demonstrated a MM ́ ´hotspot´´ for women, 
consisting of 20 parishes with shared borders in the city area of Aalborg and within 
10km from asbestos plants (Figure 3-2.4). In these parishes, the MM cumulative 
incidence ranged 0.72–7.21/100,000 person-years versus 0.69/100,000 person-years 
for Denmark. Women residing in these parishes had also higher RR of MM than the 
Danish women. Particularly the parish where DAF was located had the highest 
incidence of 7.21 per 100,000 person-years and the highest RR for MM (RR=10.5 for 
all the patients, RR=2.9 for the environmentally exposed) compared to the rest of 
Denmark (Figure 3-2.4, Appendix B). 
Study IIb 
 
Study IIb revealed a similar ´´hotspot´´ of 16 continuous parishes within a 10km 
radius from asbestos industries for the male population. Inside this ´´hotspot´´, the 
cumulative incidence per 100,000 person-years for MM was higher than the other 
parishes of the North Denmark Region, for both the occupationally and non-
occupationally exposed male MM patients (Figure 3-2.5, Appendix B). When all 
exposure types were taken into consideration, the male residents of ten parishes inside 
this ´´hotspot´´ had higher RR of MM compared to the Danish men (Table 3-2.3). The 
highest cumulative incidence and RR of all was recorded in the parish, where Aalborg 
shipyard was located, whereas the parish where DAF operated, presented with the 
fourth highest RR (Table 3-2.3). 
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Figure 3-2.4. Malignant mesothelioma incidence for women in the parishes of the Region of 
North Denmark (a, b) and the city of Aalborg (c, d). Further information about the parishes 
shown in figures 3-2.4a/4c and 3-2.4b/4d can be found in Tables 1a and 1b in the Appendix B, 
respectively. The Aalborg shipyard (upper) and the Danish asbestos cement factory (lower) are 
illustrated as blue triangles. White areas on the map have no MM female cases in 1974–2015. 
 
 
 
Figure 3-2.5. The cumulative incidence per 100,000 person years for malignant mesothelioma 
for men in the parishes of the Region of North Denmark (a, b) and the city of Aalborg (c, d). 
Further information about the parishes shown in figures 3-2.5a/5c and 3-2.5b/5d can be found 
in Tables 2a and 2b in the Appendix B, respectively. The Aalborg shipyard (upper) and the 
Danish asbestos cement factory (lower) are illustrated as white stars. White areas on the map 
have no MM male cases in 1970–2015. 
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Parish 
name 
 
Parish 
number 
Number 
of MM 
cases 
Cumulative 
incidence per 
100,000 
person- years 
RR 
(Parish
/ DK*) 
95% CI 
Vejgaard 2 29 10.02 4.09 2.84, 5.89 
Sankt 
Markus 
3 25 15.06 6.14 4.15, 9.10 
Hans 
Egedes 
1 13 7.87 3.21 1.87, 5.54 
Ansgars 5 13 8.87 3.62 2.10, 6.23 
Lindholm 6 11 5.60 2.28 1.26, 4.12 
Budolfi 10 10 7.32 2.98 1.61, 5.55 
Noevling 12 9 11.45 4.67 2.43, 8.97 
Vesterkaer 40 9 11.26 4.59 2.39, 8.82 
Vodskov 41 7 6.57 2.68 1.28, 5.62 
Svenstrup 301 7 6.14 2.51 1.19, 5.26 
* Denmark (DK) has a cumulative incidence of male MM of 2.45 per 100,000 person years. 
 
Table 3-2.3. Representation of the cumulative incidence and relative risk of MM for the male 
residents of parishes in the North Denmark Region (all types of exposure are taken into 
consideration). DAF was located in parish number 2 and Aalborg shipyard in parish number 3.  
 
 
3.2.2.3 Asbestos Exposure Patterns and Disease Characteristics 
 
Study IIa 
The main sources of asbestos exposure for the women were environmental (N=21, 
22%), domestic (N=9, 10%) and combination of those (N=31, 34%) (Figure 3-2.6). 
The domestic exposure occurred through their husbands (N=26), fathers (N=7), sons 
(N=4) or both husbands and sons (N=3), who were asbestos workers (Table 3-2.4). 
The women with non-occupational exposure to asbestos tended to develop MPM 
(N=54) rather than MPeM (N=7), whereas occupationally exposed developed MPeM 
(N=3) rather than MPM (N=5) (p=0.046) (Figure 3-2.6). 
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Figure 3-2.6. Types of asbestos exposure for the 91 women MM, then further categorized in 
cases with MPM and MPeM. 
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Number of cases Relatives workplace or employment type 
11 Aalborg Shipyard 
11 DAF 
8 Construction worker 
2 Worker at pipe factory 
2 Insulator 
2 Electrician 
1 Car mechanic 
1 Engineer 
1 DAF and Aalborg Shipyard 
1 Worker installing asbestos roof 
 
Table 3-2.4. Employment information for the relatives of the female MM patients. The data 
resulted from assessment by an occupational health expert and from data from the Danish 
Supplementary Pension Fund Registry and the Danish Civil Registration System. 
 
Study IIb 
In this study, 66% (N=282, male:female ratio of 34:1) of the patients had occupational 
and 25% (N=105, male:female ratio of 1:1.4) non-occupational asbestos exposure, 
including 60 cases (14%, male:female ratio of 1.9:1) with pure environmental 
exposure. The men and the women had significantly different exposure profiles 
(p<0.0001 for all groups) (Figure 3-2.7). Most of the men had a combined 
occupational and environmental exposure (N=191, 57%) or were exposed to asbestos 
through their jobs (N=82, 25%) or environment (N=39, 12%). The most popular work 
places for the occupationally exposed patients were the shipyards (N=113, 40%), 
construction industry (N=44, 15%) and DAF (N=39, 14%) (Table 3-2.5). MPeM was 
more prevalent among women than men (p=0.016, Odds ratio (OR)=4.34, 
95%CI=[1.31,14.35]). Individuals with occupational asbestos exposure were prone to 
develop non-epitheliod MM, whereas the epithelioid subtype was more frequent in 
the non-occupationally exposed patients (p=0.008, OR=0.38, 95%CI=[0.186, 0.777]) 
(Figure 3-2.8). 
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Figure 3-2.7. Types of asbestos exposure for the total, the male and the female population. 
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Figure 3-2.8. A. The subtypes of MM for the occupationally and non-occupationally exposed 
patients. The occupationally exposed patients had an overrepresentation of non-epithelioid, 
while the non-occupationally exposed patients of epithelioid MM (p= 0.008, OR= 0.38, 
95%CI= [0.186, 0.777]). B. The location of MM for men and women. A larger proportion of 
women develop MPeM in comparison to men (0.016, OR= 4.34, 95%CI= [1.31,14.35]). 
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Profession/Industry Men, N (%) Women, N (%) 
Worker at shipyard 112 (40.9%) 1 (12.5%) 
Construction industry 44 (16.1%) 0 
Worker at DAF 36 (13.1%) 3 (37.5%) 
Unskilled laborer 29 (10.6%) 0 
Other 13 (4.7%) 3 (37.5%) 
Worker at DAF and shipyard 14 (5.1%) 0 
Smith 12 (4.4%) 0 
Electrician 7 (2.6%) 0 
Mechanic 6 (2.2%) 0 
Unknown 1 (0.4%) 1 (12.5%) 
 
Table 3-2.5. Professions of male and female MM patients that were occupationally exposed to 
asbestos. The asbestos exposure information resulted from assessment by an occupational 
health expert and from data from the Danish Supplementary Pension Fund Registry. 
 
 
3.2.3. CONCLUSION 
Study IIa showed that non-occupational asbestos exposure is the main cause of MM 
for the women in the Region of North Denmark. Furthermore, it identified a high-
incidence and high-risk ´´hotspot´´ for the exposed population within 10km from 
asbestos industries in the city of Aalborg (Aim 2). Lastly, the study indicated that 
occupational asbestos exposure was linked to MPeM and non-occupational asbestos 
exposure was linked to MPM in women (Aim 4). 
Study IIb demonstrated that non-occupational asbestos exposure was implicated in 
the MM pathogenesis for the majority of the men (Aim 2). A similar ´´hotspot´´ with 
the one in Study IIa was defined for the male population, where the cumulative 
incidence for MM was increased compared to the North Denmark Region. Men 
residing in ten parishes inside this ´´hotspot´´ had higher RR of MM than the Danish 
men. The male and female patients were found to have profoundly different asbestos 
exposure profiles, but combined asbestos exposures was common for the total 
population (Aim 3). An overrepresentation of MPeM among women compared to men 
was noticed, while non-occupational asbestos exposure was associated to epithelioid 
and occupational exposure to non-epithelioid MM subtype (Aim 4). 
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3.3. STUDY III 
 
3.3.1. MATERIALS AND METHODS 
3.3.1.1 Study population 
The study population consisted of MM patients treated at the University of Chicago 
MM clinic during April 2016-August 2017 and of deceased patients who had 
previously consented to a tumor-bank protocol. Two trained interviewers used a 
standardized questionnaire to obtain detailed information about personal and family 
history of cancer and asbestos exposure from all the patients. Asbestos exposure was 
grouped as primary for occupationally exposed individuals and secondary, for 
domestic and environmental exposure. Further clinical information was acquired from 
the medical records. 
 
3.3.1.2 Germline Mutations 
A targeted gene panel, designed by The University of Chicago Genetic Services 
Laboratory was used on saliva or peripheral blood from the included patients to 
sequence 85 cancer susceptibility genes in order to identify pathogenic and likely 
pathogenic germline variants (Table 3-3.1). Nonsense, frameshift, splice site, and 
missense variants with known damaging effect on protein function, in genes with 
known moderate-to-high penetrance cancer susceptibility were included in the study. 
Sanger sequencing validated all the genetic findings, and they were correlated with 
the clinical information and family history, as well. The frequency of germline 
mutations for a non-cancer population was assessed through the Exome Aggregation 
Consortium (ExAC). All genetic analyses were performed according to the American 
College of Medical Genetics guidelines. 
 
 
 
 
 
 
RISK FACTORS AND BIOMARKERS FOR MALIGNANT MESOTHELIOMA 
56
 
ANKRD26 APC ATM BAP1 BARD1 BLM 
BMPR1A BRAF BRCA1 BRCA2 BRIP1 CDH1 
CDK4 CDKN1B CDKN2A CEBPA CHEK2 CTNNB1 
DKC1 EPCAM FANCA FANCB FANCC FANCD2 
FANCE FANCF FANCG FANCI FANCL FANCM 
FH FLCN GATA2 GREM1 HRAS KIT 
KRAS MAX MEN1 MET MITF MLH1 
MLH3 MRE11A MSH2 MSH3 MSH6 MUTYH 
NBN NF1 NF2 PALB2 PAX5 PDGFRA 
PIK3CA PMS1 PMS2 POLD1 POLE PTCH1 
PTEN PTPN11 RAD50 RAD51 RAD51C RAD51D 
RET RUNX1 SDHA SDHAF2 SDHB SDHC 
SDHD SLX4 SMAD4 SMARCA4 STK11 TERC 
TERT TMEM127 TP53 TSC1 TSC2 VHL 
WT1      
 
Table 3-3.1. The panel of the 85 cancer susceptibility genes targeted and sequenced using a 
custom assay developed by The University of Chicago Genetic Services Laboratory.  
 
 
3.3.1.3 Somatic Mutations and Functional Tumor Studies 
DNA was extracted from fresh-frozen, paraffin-embedded MM samples from two 
next-generation sequencing platforms, UCM-OncoPlus (N=147 gene panel) and 
Foundation Medicine (N=315 gene panel), in order to inspect for somatic mutations 
(Appendix C).  
3.3.1.4 Statistical Analysis 
Two-sided Fischer’s exact test, Wilcoxon signed-rank test and logistic regression 
were used, as described above (under 3.2.1.4). Likelihood ratio tests were utilized to 
compare nested models and two-sided exact binomial test to compare the frequency 
of germline mutations. Statistical significance was reached when p < 0.05. 
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3.3.2. RESULTS 
3.3.2.1 Population Demographics 
There were 250 current and 12 historical patients that were taken into consideration 
for Study III; of those, 198 had sufficient germline DNA available and were included 
in the study (Figure 3-3.1). The population characteristics are summarized in Table 3-
3.2. Twenty-seven of the patients (14%) had additional primary cancer diagnoses, and 
173 (87%) of their first (FDR) and/or second (SDR) degree relatives, were previously 
diagnosed with cancer, as well (Table 3-3.3). Thirteen of the patients of this cohort 
had one or more FDR or SDR with MM. 
 
 
Figure 3-3.1. Consort diagram for Study III. 
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  N (%) 
Total 198 (100) 
Sex   
  Male 136 (69) 
Age at diagnosis, median (IQR) 67 (59, 73) 
Ethnicity   
  Non-Hispanic white  192 (97) 
  Black 3 (2) 
  Asian 3 (2) 
Site of origin   
   Pleura 148 (75) 
   Peritoneum 44 (22) 
   Pleura & Peritoneum 3 (2) 
   Tunica vaginalis 3 (2) 
Histology   
   Epithelioid 157 (79) 
   Sarcomatoid 13 (7) 
   Biphasic 23 (12) 
   Unknown 5 (3) 
Additional cancer primary*   
   Yes^ 27 (14) 
        Hematologic 8 (4) 
        Breast 7 (4) 
        Prostate 5 (3) 
        Melanoma 4 (2) 
        Colon 2 (1) 
        Renal 2 (1) 
        Other 3 (2) 
FDR with cancer*   
   Yes 142 (72) 
   No 54 (27) 
   Unknown 2 (1) 
FDR and/or SDR with cancer *   
   Yes 173 (87) 
   No 23 (12) 
   Unknown 2 (1) 
Asbestos exposure   
   Definite 104 (53) 
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   Probable 22 (11) 
   Possible 35 (18) 
   None 35 (18) 
   Unknown 2 (1) 
Type of asbestos exposure#   
   Primary 98 (49) 
   Secondary 32 (16) 
   Primary & Secondary 31 (16) 
Smoking status   
   Current 1 (1) 
   Former 89 (45) 
   Never 106 (54) 
   Unknown 2 (1) 
Treatments received for MM   
   Curative intent surgery 100 (51) 
   Chemotherapy 165 (83) 
   Platinum-based chemotherapy 159 (80) 
*excludes non-melanoma skin cancer 
^27 subjects had 31 total additional cancer primaries; other includes ovarian cancer (1), Wilm's 
tumor (1), and gastrointestinal stromal tumor (1) 
#Asbestos exposure type for the N=161 subjects with possible, probable, or definite exposure 
 
Table 3-3.2. Patient characteristics 
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Cancer Type FDR FDR and/or SDR 
Breast 41 67 
Colorectal  30 46 
Lung 27 53 
Prostate  27 40 
Melanoma 10 11 
Leukaemia 10 15 
Brain  9 16 
Lymphoma 8 14 
Mesothelioma 8 14 
Pancreas  8 13 
Ovarian  8 11 
Hepatic  7 9 
Head & Neck 6 12 
Thyroid  6 8 
Urinary tract 6 8 
Renal  5 8 
Uterine  5 8 
Multiple myeloma 4 5 
Cervical  3 4 
Gastric  2 12 
Retinal  1 2 
Bone  1 3 
Wilm's tumor  1 1 
 
Table 3-3.3. Total number of first- (FDR) and/or second-degree (SDR) relatives with specific 
cancers in family histories from patients with MM 
 
3.3.2.2 Germline Mutations 
The analysis identified 24 germline mutations in 23 (12%) of the 198 MM patients 
(one patient carried two germline mutation, one in BAP1 and one in TMEM127). 
There were 13 different genes that presented with the 24 mutations, with BAP1 the 
most common (N=6, 25%) (Figure 3-3.2). Three of the 13 families with more than 
one MM cases carried a germline mutation, all in BAP1. 
Certain clinical characteristics could predict the presence of germline mutations, 
including peritoneal disease, limited or no asbestos exposure, second cancer diagnosis 
and younger age (Figure 3-3.3, Table 3-3.4, Table 3-3.5). There was no significant 
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association between germline mutations and sex, histology, FDR/SDR with cancer, 
including MM, and smoking status.  
A germline mutation in BAP1 (OR=1.658, 95%CI=[199, 76,224], p= 0.001), BRCA2 
(OR=5, 95%CI=[1.0, 14.7], p=0.03), CDKN2A (OR=53, 95%CI=[6, 249], p=0.001), 
TMEM127 (OR=88, 95%CI=[1.7, 1,105], p=0.01), VHL (OR=51, 95%CI=[1.1, 453], 
p=0.02), and WT1 (OR=20, 95%CI=[0.5, 135], p=0.049) was significantly more 
frequent in our study population compared to the non-cancer ExAC population (Table 
3-3.6). 
 
3.3.2.3 Somatic mutations 
There were 54 patients with available MM tissue to undergo tumor sequencing, hereof 
37 MPM and 17 MPeM samples. The most common acquired mutations were 
identified in BAP1, in 13 MPM (43%) and 11 MPeM (65%) specimens, and only two 
out of the 31 different mutations (6%) were germline (Figure 3-3.4 and Appendix C).  
Acquired mutations were also frequent in CDKN2A (N=10, 19% of N=54), NF2 
(N=10, 19% of N=54), SETD2 (N= 6, 11% of N=54), DDX3X (N=4, 7% of N=54), 
and FBXW7 (N= 4, 7% of N=54) for both MPM and MPeM, while TP53 was only 
mutated in MPM cases (N=7, 19% of N=37). Interestingly, one or more germline or 
acquired mutations in a homologous recombination (HR) DNA repair pathway gene 
was found in 29/54 (52%) samples. Five of the patients with germline mutations had 
available tumor tissue for sequencing. Two of them had an inherited BAP1 mutation 
and the other three had a WT1, CHEK2 and ATM mutation, respectively (Appendix 
C, UC016, 059, 041, 102, and 170). In the tumor samples of the mutation carriers, 0-
3 somatic mutations were discovered; both patients with germline BAP1 mutations 
and the individual with the WT1 mutation acquired a second pathogenic BAP1 
mutation.  
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Figure 3-3.2. Twenty-four germline mutations were identified in 13 different genes in 23 
patients (12% of N=198). 
 
 
Figure 3-3.3. Proportions of the germline mutation-carriers per clinical features. 
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  Germline 
mutation 
No germline 
mutation 
 
P-value 
Total, No. (%) 23 (12) 175 (88)   
Sex       
  Female 9 (39) 53 (30) 0.47 
  Male 14 (61) 122 (70)   
Age at diagnosis, median (IQR) 61 (56, 71) 67 (59, 73) 0.04 
Site of origin       
   Pleura 11 (48) 137 (78) 0.01 
   Peritoneum 11 (48) 33 (18)   
   Pleura & Peritoneum 1 (4) 2 (1)   
   Tunica vaginalis 0 (0) 3 (2)   
Histology (N=193)       
   Epithelioid 21 (95) 136 (80) 0.26 
   Sarcomatoid 0 (0) 13 (7)   
   Biphasic 1 (5) 22 (13)   
Additional cancer primary**       
   Yes 7 (30) 20 (11) 0.02 
   No 16 (70) 155 (89)   
FDR with cancer**       
   Yes 17 (74) 119 (69) 0.81 
   No 6 (26) 54 (31)   
Asbestos exposure (N=196)*       
   Definite 7 (30) 97 (56) 0.02 
   Probable 4 (17) 18 (10)   
   Possible 3 (13) 32 (19)   
   None 9 (39) 26 (15)   
Type of asbestos exposure 
(N=161)* 
      
   Primary 7 (50) 91 (62) 0.62 
   Secondary 4 (29) 28 (19)   
   Primary & Secondary 3 (21) 28 (19)   
Smoking status (N=195)*       
   Current 0 (0) 1 (1) 0.28 
   Former 7 (30) 82 (47)   
   Never 16 (70) 90 (52)   
*Patients with missing values excluded.. **Excludes non-melanoma skin cancer. 
 
Table 3-3.4. Clinical characteristics of germline mutation carriers and non-mutation carriers. 
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Variable OR 
(95% 
CI) 
P-
value 
M.1 
OR 
(95% 
CI) 
P-
val
ue 
M.2 
OR 
(95% 
CI) 
P-
valu
e 
M.3 
OR 
(95% 
CI) 
P-
val
ue 
Male 0.69 
(0.28-
1.70) 
0.42 
      
Histology~ 
        
Epithelioid 1.00 
       
Sarcomatoid 1.00 
       
Biphasic 0.29 
(0.04-
2.25) 
0.24 
      
Age, 
median* 
0.95 
(0.92-
0.99) 
0.01 0.96 
(0.92-
0.99) 
0.02 
  
0.97 
(0.93-
1.01) 
0.13 
Site of 
origin^ 
        
Peritoneum 
or Both 
1.00 
   
1.00 
 
1.00 
 
Pleura 0.23 
(0.10-
0.58) 
0.002 
  
0.31 
(0.12-
0.80) 
0.02 0.44 
(0.15-
1.27) 
0.13 
Second 
cancer  
3.33 
(1.22-
9.07) 
0.019 3.45 
(1.18-
10.15
) 
0.02 2.27 
(0.77-
6.70) 
0.14 2.73 
(0.89-
8.39) 
0.08 
Asbestos 
exposure 
0.28 
(0.11-
0.72) 
0.008 0.33 
(0.12-
0.89) 
0.03 0.34 
(0.13-
0.90) 
0.03 0.35 
(0.13-
0.95) 
0.04 
M.1: Age, Asbestos & Second cancer 
M. 2: Site of origin, Asbestos & Second cancer 
M.3: Age, Site of origin, Asbestos & Second cancer  
~Sarcomatoid category has zero germline mutation carriers  
*Age centered around median of 67 years    
^tunica vaginalis cases N=3 were excluded from these analyses  
#Nested models (M.1 vs M.3 and M.2 vs M.3) were compared using likelihood ratio tests; 
Addition of the site of origin in either comparison did not improve model fit (p=0.13) 
 
Table 3-3.5. Predictors of a germline mutation among patients with MM. 
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 University of Chicago 
Patients with MM 
N=198 
ExAC Non-Cancer 
Population 
N=53,105*  
University of 
Chicago versus 
ExAC population 
Gene Mutated 
alleles 
(N) 
Proportion 
of 
individuals 
with a 
mutation 
Mutated 
alleles 
(N) 
Proportion 
of 
individuals 
with a 
mutation 
OR 
 (95% 
CI) 
P-
value 
** 
BAP1 6 0.0303 1 0.0303 1657.5 
(199-
76,224) 
<.001^ 
BRCA
2 
3 0.0152 167 0.0152 4.9 (1.0-
14.7) 
0.03 
CDKN
2A 
2 0.0101 10 0.0101 52.6 (6-
249) 
<.001^ 
TMEM
127 
1 0.0051 3 0.0051 88.4 
(1.7-
1,105) 
0.01 
VHL 1 0.0051 5 0.0051 50.5 
(1.1-453) 
0.02 
WT1 1 0.0051 13 0.0051 20.1 
(0.5-135) 
0.049 
ATM 2 0.0101 155 0.002929 3.5 (0.4-
12.9) 
0.12 
CHEK
2 
3 0.0152 770 0.015480 0.98 
(0.2-2.9) 
1.00 
BRCA
1 
1 0.0051 102 0.002000 2.5 (0.1-
14.6) 
0.33 
MRE1
1A 
1 0.0051 33 0.000625 8.1 (0.2-
49) 
0.12 
TP53 1 0.0051 29 0.000548 9.3 (0.2-
56.4) 
0.10 
MSH6 1 0.0051 102 0.001934 2.6 (0.1-
15) 
0.32 
SDHA 1 0.0051 53 0.001026 4.9 (0.1-
29) 
0.18 
*Number of individuals sequenced varies by genomic position  
**Two-sided exact binomial tests without adjustment for multiple testing  
^Remain significant at alpha<0.004 if Bonferroni correction is used  
 
Table 3-3.6. Mutation frequencies in patients with malignant mesothelioma versus a non-cancer 
population estimate 
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*Origin:  Dark blue=pleural; light blue=peritoneal 
**Histology:  Dark red=epithelioid, pink=biphasic, green=sarcomatoid 
Abbreviations:  VUS=variant of uncertain significance 
Mutation types:  loss, large deletion or duplication, nonsense, frameshift, splice site=dark gray; 
missense, in frame deletion, promoter mutation=green; amplification= blue; germline variants 
are notated by a ★.  
Tumors with multiple variants in the same gene are notated with the number of unique variants 
identified. 
 
Figure 3-3.4. Genetic variants identified by site of origin and histology in 54 MM specimens 
 
 
 
3.3.3. CONCLUSION 
Study III identified 13 different genes that presented with 24 germline mutations in 
23/198 MM patients. The spectrum included inherited mutations in the well-
characterized gene BAP1, in previously reported genes in case reports (BRCA2, 
CDKN2A, ATM, BRCA1, TP53, MSH6) and novel genes in the MM context 
(TMEM127, CHEK2, MRE11A, VHL, WT1, and SDHA) (Aim 5). Germline mutations 
in BAP1, BRCA2, CDKN2A, TMEM127 and WT1 were overrepresented among the 
MM patients in comparison to a non-cancer population (Aim 5). The study concluded 
that peritoneal disease, no known asbestos exposure, second cancer diagnosis and 
younger age were significant predictors of a germline mutation (Aim 6). The HR DNA 
repair pathway was implicated in more than half of the MM cases, either as a result 
of a germline or a somatic mutation (Aim 7). 
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CHAPTER 4. DISCUSSION 
The aims and the main conclusions, as well as the clinical impact and the 
methodological considerations of the thesis will be discussed in this chapter. 
 
4.1. AIM 1 
To summarize the most important current and most promising future biomarkers 
within the diagnosis, prognosis and prediction for MM. 
Study I attempted to assess Aim 1 by providing an overview of the most important 
studies and describing the biomarkers that are currently essential to the MPM 
diagnosis, as well as the most promising diagnostic, prognostic and predictive 
biomarkers. The evident diverging results of the numerous studies about MM 
biomarkers are a consequence of the lack of standardized treatments and assays, the 
rarity and aggressiveness of the disease and the limited number of patients that hamper 
the conclusiveness of the results. The consensus statement for the pathologic MM 
diagnosis established by the International Mesothelioma Interest Group included 
typically calretinin and one other positive marker (e.g. cytokeratin 5, podoplanin or 
WT1) and two negative markers (149). The consensus statement and the four-
biomarker-panel have enhanced the accuracy of the immunohistochemical 
classification but the available positive markers are of limited sensitivity. Calretinin 
is one of the most valuable immunohistochemical markers for the MM diagnosis and 
it was routinely introduced in the pathologic laboratories in the late 1990s (149). 
However, calretinin is negative in half of the cases of sarcomatoid MM, while it can 
also be positive in some cases of lung adenocarcinoma, breast, serous, renal cell, small 
cell and squamous cell carcinoma (focal reaction) (150,151). Similarly, cytokeratin 5 
is positive in all squamous cell, and occasionally in other carcinomas, while benign 
fibrosing lesion may express podoplanin (89,90,92,93). WT1 has no value in the 
differential diagnosis of breast cancer and serous carcinomas of the ovary and 
peritoneum (95).  
Some potential biomarkers or panels of biomarkers for the diagnosis, prognosis, 
prediction and early detection of MM have shown interesting results and warrant 
further investigation. Furthermore, several biomarkers have been proposed as a cost-
effective means of treatment but there are contradicting findings as to their sensitivity 
and specificity (126,152). Mesothelin, the most promising current MM biomarker and 
the only one that is commercialized, is specific but not sensitive, as it can be elevated 
in other malignant and non-malignant diseases, such as renal failure, as well 
(116,122). Moreover, it is documented that mesothelin serum levels can decrease at 
response to treatment with tumor shrinkage in some (but far from all) patients; 
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however, it is not of clinical utility due to the low robustness (116). The role of 
mesothelin in MM screening has also been investigated with overall discouraging 
results (116). The diagnostic utility of osteopontin is controversial, as some studies 
have shown that osteopontin levels have prognostic and/or predictive value and high 
levels of osteopontin were individually associated with worse prognosis, but other 
researchers did not reach the same conclusions (124,125). Fibulin-3 has shown 
potential in distinguishing MPM patients from an asbestos-exposed non-cancer 
population and in monitoring the progress of the disease, but the same findings were 
not confirmed in subsequent studies (133,153). Hyaluronate is prevalent in progressed 
MPM but it is also elevated in other pathologies, such as inflammatory joint disease 
and hepatic fibrosis, thus its diagnostic utility is limited (154). Several micro-RNAs 
have been suggested by profiling studies but only two microRNA signatures  (miR-
16-5p/miR-126-3p/miR-143-3p/miR-145-5p/miR-192-5p/miR-193a-3p/miR-200b-
3p/miR-203a-3p/miR-652-3p and miR-126-3p/miR-103a-3p/miR-625-
3p/mesothelin) proved to be of value as to early diagnosis according to a meta-analysis 
and functional studies, while large-scale validation is required (155). The role of long 
non coding RNA in MPM is being investigated the recent years but is yet to be fully 
understood (156). The lack of validation for proteomics, gene expression profiling, 
deformability cytometry, fluorescence in situ hybridization assay and selected 
reaction monitoring assay technology impedes their use in the clinic. In conclusion, 
non-invasive markers of higher sensitivity and specificity are being explored but most 
of them are not further assessed beyond the initial discovery phase (126,152). 
Therefore, their potential is limited and their clinical use is unlikely in the near future. 
However, prognostic and predictive biomarkers able to separate responders from non-
responders would assist clinicians in the management of MM, and they would spare 
the patients from ineffective treatment and the society from unnecessary costs 
(126,152). Furthermore, biomarkers that would enable the detection of the high-risk 
asbestos exposed individuals, would facilitate the early diagnosis of the disease. 
In summary, the current diagnostic, prognostic and predictive MM biomarkers are 
inadequate but new are constantly emerging. Hence, there is a need for further 
research in order to discover new, and large prospective studies in order to validate 
the prevailing biomarkers for MM. 
 
4.2. AIM 2 
To explore the extent and impact of non-occupational asbestos exposure for women 
and men with MM. 
Aim 2 was investigated in Study IIa and IIb. We concluded that 25% of the total 
population had non-occupational exposure to asbestos, including 60 patients (14%) 
with sole environmental exposure. In particular, 23% of the women and 12% of the 
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men had a sole environmental exposure, whereas 57% of the male patients had a 
combined occupational and environmental exposure. A ´´hotspot´´ of 20 parishes with 
shared borders within 10km from asbestos plants in the city of Aalborg was defined 
in Study IIa, where the incidence and RR of MM for women was higher than the rest 
of Denmark. Particularly, the parish, where DAF was located presented with the 
highest incidence and RR for MM. A corresponding ´´hotspot´´ of 16 continuous 
parishes within a 10km radius from asbestos industries was identified through Study 
IIb, where the cumulative incidence of MM for men was increased compared to the 
rest of the Region of North Denmark. Ten parishes, whose male residents had higher 
RR of MM than the Danish men, were also part of this ´´hotspot´´. The parish where 
Aalborg shipyard was located had the highest RR of all and the parish where DAF 
operated, presented with the fourth highest RR. 
Environmental exposure to asbestos is often neglected and under-reported and MM 
patients with this type of exposure are not entitled to financial compensation. The 
most comprehensive studies regarding environmental asbestos exposure and MM risk 
come from the Italian national registry of MM, and especially three cities in northwest 
Italy, Casale Monferrato, Bari and Broni (21,28,157,158). These cities have had heavy 
asbestos burden, as large asbestos cement plants were operating for decades in densely 
populated areas and thus, the residents have suffered a high MM incidence without 
direct occupational exposure. However, the impact of heavy asbestos industry 
operating in the city of Aalborg for more than six decades had not been evaluated 
before. The afore-mentioned studies describe MM ´´hotspots´´ around asbestos 
industries and usual characteristics of environmental exposure, such as long disease 
latency and duration of exposure, which are observed in our cohort, as well. These 
findings corroborate that large-scale environmental asbestos contamination took place 
in Aalborg. This extended environmental asbestos pollution contributed to the 
increased incidence and RR of MM for both men and women around asbestos 
industries in Aalborg in comparison to less contaminated geographical areas. 
The role of domestic asbestos exposure in MM carcinogenesis has been documented 
in the literature but the detailed study of MM due to this type of exposure is obstructed 
due to the long latency period and the small number of patients (20,159,160). Several 
hundred MM cases have been reported among family members of asbestos workers 
and studies have shown that there is a five-fold increased risk of MM for case-control 
studies and 8.5-fold risk for cohort studies of domestically exposed individuals 
(23,161). The family members include typically fathers, brothers and sons that work 
as miners, manufacturers of asbestos-containing products, insulators, shipyard and 
construction workers, which is concordant with our findings (23,24). The fiber type 
is not always taken into account in the published research, but the majority of the 
studies describe MM patients that have been domestically exposed to amphiboles; 
thus the impact of household exposure to chrysotile is under-investigated (24). This 
is not the case with our cohort, where one fourth of the women had been domestically 
exposed to chrysotile asbestos, as their relatives were employed at DAF and 
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construction industry. The long latency of 20-70 years is responsible for the constantly 
increasing MM incidence for the population of the North Denmark Region. As 
asbestos was banned in the late 1980´s, the incidence peak is yet to be reached. 
In summary, our observations strongly suggest that non-occupational asbestos 
exposure has had a major impact on the male and female population of the Region of 
North Denmark, with the population at the highest risk residing within 10 km from 
asbestos industries. According to our findings, the clinicians need to be cautious with 
the assessment of the risk of MM as a result of non-occupational exposure to asbestos. 
To our knowledge, this is the first large study to thoroughly evaluate the effect of 
asbestos exposure for the total population of the Region of North Denmark and the 
first of its kind in the Scandinavian countries. Study IIa along with previous research 
of our research group members led to the re-evaluation of the rules of financial 
compensation for MM patients that have been domestically exposed to asbestos in 
Denmark.  
 
4.3. AIM 3 
To elucidate and compare the asbestos exposure patterns for the male and the female 
MM patients. 
The asbestos exposure profiles of the women and men with MM were examined in 
Study IIa and IIb, respectively, while the comparison of the two profiles was 
performed in Study IIb. The vast majority of the women had a sole or combined non-
occupational exposure to asbestos, while only 9% of them had worked with asbestos. 
On the contrary, 82% of their male counterparts had a sole or combined occupational 
asbestos exposure (male:female ratio of 34:1 for occupational exposure). On the other 
hand, sole or combined domestic exposure to asbestos was common for the female 
but very uncommon for the male population (44% versus 1%, respectively and a 
male:female ratio of  1:8). In the literature, several cohorts are encountered, where the 
women have a high rate of non-occupational and the men of occupational asbestos 
exposure (40,162,163). However, the small fraction of occupationally exposed 
women of this population is atypical. This is probably a direct aftermath of the fact 
that, historically, the asbestos workers in the Region of North Denmark have been 
men. The jobs of the occupationally exposed patients are similar to the previously 
reported high-risk occupations, such as workers at a shipyard, the construction 
industry and the DAF (40,164,165). The finding that 25% of the MM patients were 
employed at DAF and construction industry presents with a particular interest, as it 
confirms that chrysotile is definitely carcinogenetic, in line with the World Health 
Organization and in contrast to some researchers that even recently question the role 
of chrysotile in MM tumorigenesis (166–168). Environmental asbestos exposure is 
present at both groups with a male:female ratio of 1.9:1. A male:female ratio close to 
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1 would be expected in this cohort, as both men and women were equally subjected 
to the environmental asbestos contamination. Unregistered recreational use of 
asbestos could account for some of the environmental MM cases among men. There 
is also a small difference regarding the unknown exposure, as it is more frequent 
among women compared to men. A high rate of unknown exposure for female MM 
patients has been described in previous studies, but one needs to address this 
observation cautiously, as it is not clear whether there is a real absence of asbestos 
exposure or if the non-occupational asbestos exposure sources were poorly evaluated 
(40,54,169,170). Interestingly, more than half of the men and more than one third of 
the women had a combined asbestos exposure. The most frequent combined 
exposures were occupational and environmental for men, and domestic and 
environmental for women. The fact that more than 50% of the male and female MM 
patients were born and raised within 10km from DAF and Aalborg shipyard is the 
reason for this observation. The potential contribution of the extra burden of combined 
environmental exposure to the high cumulative incidence and RR of MM inside the 
´´hotspot´´ is difficult to assess. There are not many studies identifying combined 
exposure to asbestos and as result, the consequences hereof are not known. 
In summary, the men and women of the Region of North Denmark had profoundly 
different exposure profiles, with domestic and/or environmental exposure being most 
common for the female and occupational and/or environmental exposure for the male 
cohort. Combined exposure was very frequent for both populations. 
 
4.4. AIM 4 
To examine whether the histopathological MM subtype, epithelioid or non-epitheliod, 
and the MM location, pleura or peritoneum, are associated with the type of asbestos 
exposure or the gender of the patient. 
Both Study IIa and Study IIb attempted to elucidate this matter. The fact that the type 
of asbestos exposure could affect the development of MPeM or MPM in women 
(Study IIa), indicates that more intense, occupational exposure may predispose to 
peritoneal while lighter, non-occupational exposure to pleural disease. There are 
previous studies that reached the same conclusion, but the retrospective nature of the 
study and the relatively small number of patients call for further validation (171,172). 
Study IIb showed that MPeM was overrepresented among women in comparison to 
men. This could be associated with the different pathways that are involved in MPeM 
carcinogenesis and might imply a general susceptibility of women to MPeM due to 
hormonal, anatomical or genetic dissimilarities (40,173). Additionally, the epithelioid 
MM subtype was linked to non-occupational, while the non-epithelioid subtype to 
occupational asbestos exposure, which suggests that less intense (non-occupational) 
asbestos exposure might predispose for the less aggressive epithelioid MM subtype 
CHAPTER 4. DISCUSSION 
73 
and vice versa (101). The literature presents contradicting results on the subject. Some 
studies have illustrated that heavier and longer asbestos exposure could predispose to 
non-epithelioid subtypes, but others found no association between the frequency or 
intensity of asbestos exposure and the histopathological MM subtype (5–7). 
In summary, there are indications that the type of asbestos exposure might influence 
the MM location in women. Similarly, the development of pleural or peritoneal 
disease seems to be influenced by gender in the total population, whereas the 
development of epithelioid or non-epithelioid subtype might be affected by the type 
of asbestos exposure. However, validation of these hypotheses on larger populations 
is necessary before definitive conclusions can be drawn. 
 
4.5. AIM 5 
To assess the prevalence and the spectrum of germline mutations in MM. 
Aim 5 was addressed in Study III. MM was considered to be a highly exposure based 
tumor but we found that 12% of the population carried germline mutations in cancer 
susceptibility genes. The prevalence described for other malignancies, e.g. metastatic 
prostate cancer, is quite comparable to the identified proportion of germline mutations 
in MM, substantiating our observation (174). The well-described BAP1 was 
responsible for 25% of the mutations, but 12 additional genes were identified, as well, 
whilst six of them were not previously associated with MM. This finding could 
provide an explanation for MM patients that presented with a suspicious personal or 
family history of malignancy but had no inherited BAP1 mutation; a germline 
mutation in another gene could be the case. Half of the identified genes (BAP1, 
BRCA2, CDKN2A, TMEM127, VHL and WT1) were significantly overrepresented in 
the MM versus a non-cancer population, supporting the hypothesis that inherited 
predisposition has a causative role in MM tumorigenesis. This is demonstrated for 
other malignancies, e.g. breast and ovarian cancer, where pathogenic genes were 
found to be overrepresented in cancer patients in comparison to the non-cancer 
population, but it was never before reported for MM (174,175). In general, the 
literature describing inherited mutations for MM patients in genes other than BAP1 is 
very limited. Inherited mutations in ATM, CDKN2A, BRCA1, BRCA2, MSH6, MLH1, 
PALB2, and TP53 have been reported in individual patients but their prevalence was 
not assessed (70,71,176). Recently, Betti et al. detected germline mutations in DNA 
repair genes in 9.7% of a MM population, including BRCA1, BRCA2, PALB2, ATM, 
FANCI, FANCC, FANCF and SLX4 (69). The authors hypothesized that DNA damage 
could not be repaired because of the genes defect, which resulted in MM genesis (69). 
However, no previous study has provided sufficient proof of causation between MM 
and inherited mutations besides BAP1. Emerging research is contributing to the 
identification of the full spectrum of inherited predisposition for MM. 
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In summary, the spectrum of germline mutations in MM includes 13 cancer 
susceptibility genes, where BAP1 accounts for one fourth of the cases. The prevalence 
of these mutations is higher than previously reported, indicating that germline 
mutations might be a universal feature of substantial subset of all cancers, including 
MM. This is the first large-scale sequencing study of germline mutations in MM 
demonstrating the causative role of susceptibility genes for MM (besides BAP1) and 
its findings were supported by subsequent research. 
 
4.6. AIM 6 
To determine disease characteristics that can predict the presence of a germline 
mutation. 
Study III shed light on this question. Clinical features that could predict the presence 
of a germline mutation include limited or no asbestos exposure, peritoneal disease, a 
previous second cancer diagnosis and younger age. Limited or no asbestos exposure 
has been established for BAP1 mutation carriers and is confirmed for all the mutation 
carriers by our data (177). A pathogenic gene alteration could be de novo 
carcinogenetic even in the absence of asbestos exposure or it might be a result of gene-
environment interaction. This gene-environment interaction has been previously 
described in MPeM, as well, in the context of its weaker association with asbestos 
exposure in comparison to MPM (178–180). In our findings, it is noteworthy that 25% 
of the MPeM patients presented with a genomic alteration versus 7% of the MPM 
patients. This increased prevalence indicates that genetic susceptibility may play a 
more important part in MPeM pathogenesis than in MPM. The fact that mutation 
carriers develop MM at a younger age and have significantly more additional primary 
malignancies is not surprising; inherited mutations are known to be linked with higher 
risk of cancer and early-onset cancer diagnosis (181). Clinical features that can predict 
an inherited mutation are infrequently reported; early age at MM onset and no asbestos 
exposure are the two common characteristics that have been described for BAP1 
mutation carriers (182,183). There are also studies that imply an increased 
susceptibility for MM for individuals with FDRs with MM and second primary cancer 
diagnosis; however, these studies did not assess the genetic status of the patients 
(184,185). 
In summary, we conclude that MM patients who present with limited asbestos 
exposure, peritoneal disease, history of additional primary malignancies and early-
onset MM diagnosis should be suspected for inherited MM susceptibility and they 
should be offered genetic counselling. The current genetic guidelines need to be 
reevaluated, though, as only half of the mutation carriers of this cohort would be 
identified by the use of the standard genetic tests. Comprehensive genetic testing 
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would allow us to identify the individuals that are in high-risk of developing a 
malignancy and, thus, to achieve early detection. 
 
4.7. AIM 7 
To explore genetic pathways in MM carcinogenesis. 
Potential genetic pathways in MM carcinogenesis were determined in Study III. More 
than half of study´s population had inherited or acquired defects in genes involved in 
the HR-mediated DNA repair pathway. Six genes with a role in this pathway carried 
germline alterations, BAP1, BRCA1, BRCA2, CHEK2, ATM and MRE11A. Somatic 
mutations were found in HR genes, as well, among others in BAP1, SETD2, FANCA 
and TP53. BAP1 mutations inhibit double strand breaks and affect the accumulation 
of proteins involved in the HR-mediated DNA damage process, while BAP1 loss is 
associated with increased sensitivity to Poly(ADP-ribose) polymerase inhibitors 
(PARPi) (186). BRCA1, BRCA2, FANCA and TP53 contribute to homology-directed 
repair of double strand breaks (187–189). CHEK2 encodes a protein that, when 
activated is known to stabilize the tumor suppressor protein p53, leading to cell cycle 
arrest (190). In addition, this protein interacts with and phosphorylates BRCA1, 
allowing BRCA1 to restore survival after DNA damage (191). ATM encodes an 
effector kinase, which regulates the activities of downstream checkpoint proteins in 
the HR pathway and MRE11A encodes a nuclear protein involved in HR, telomere 
length maintenance, and double strand breaks repair (192,193). SETD2 is required for 
the repair of double strand breaks and the activation of ATM (194). WT1 might be 
related, as well, by promoting HR-mediated DNA damage repair (195). Inherited and 
acquired mutations in genes involved in the mismatch repair pathway were also found 
(MSH6 and MLH3). Of the remaining genes with inherited mutations, VHL and SDHA 
induce carcinogenesis by modifying the hypoxia-inducible factor expression, while 
TMEM127 controls cell proliferation acting as a negative regulator of Target of 
Rapamycin signaling pathway; these constitute MM pathways that warrant 
investigation (196–198).  
The observation that a high rate of the mutated genes encode proteins involved in the 
HR-mediated DNA repair pathway has some interesting clinical implications as to 
potential chemotherapeutic targets. Alterations of the DNA repair system, either in 
germline or somatic cells can affect the prognosis and the effect of DNA damaging 
agents. Patients with breast, ovarian and prostate cancer  that are carriers of BRCA1 
and BRCA2 mutations have a better prognosis and response when treated with 
cisplatin (175,199–201). PARPi are used for these patient groups, as they are highly 
selective for tumor tissues, which are completely BRCA deficient, compared with 
normal tissues that are heterozygous at the BRCA locus (202,203). Tumors with both 
germline and somatic BAP1 alterations, resulting in total loss of the BAP1 function 
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have also been described to be sensitive to PARPi (204). Therefore, it is possible that 
MM patients with germline mutations in a DNA repair gene could also benefit from 
treatment protocols that include PARPi. Currently, two ongoing clinical trials of the 
PARPi olaparib and naraparib (Clinicaltrials.gov NCT03531840 and Clinicltrials.gov 
NCT03207347) are including patients with MM in an attempt to assess the efficacy 
of these agents in MM treatment. Additional clinical trials aiming to evaluate the 
effect of PARPi in MM patients with germline mutations would also be relevant. 
Furthermore, patients carrying germline mutations in BAP1 and other genes have 
often prolonged survival in comparison to non-mutation carriers (183). Thus, a 
germline mutation in a DNA repair gene could also serve as a prognostic marker for 
MM management. 
In summary, we describe novel germline mutations that could be implicated in the 
MM tumorigenesis, where the most common are genes encoding proteins of the HR-
mediated DNA repair pathway. Our findings may justify the sensitivity of cisplatin in 
MM and support the idea that PARPi could be an effective therapeutic strategy in MM 
(69,205). 
 
4.8. METHODOLOGICAL CONSIDERATIONS 
4.8.1. DOCUMENTATION OF ASBESTOS EXPOSURE 
One of this thesis’ primary methodological considerations is linked to the 
documentation of asbestos exposure. The Danish registries are a robust source of 
information due to the high-quality and validated data they enclose. However, the 
Danish Supplementary Pension Fund Registry includes occupational information after 
1964, thus the detailed professional history of the patients and their relatives before 
1964 was not available. The most active period of the asbestos industry was, though, 
after 1945, especially after 1960 (Figure 1-9.2), and the research group supplemented 
the occupational history by incorporating information about the patients´ work history 
through their medical records; hence, the loss of information is limited. Nonetheless, 
undocumented asbestos exposure could have taken place for some individuals of this 
cohort in relation to recreational use of asbestos or from damaged asbestos-containing 
buildings. It was not possible to exclude such exposure for the total population, as 
asbestos was a popular material in Denmark and it was broadly used until the late 
1980´s. As a result, misclassification of asbestos exposure for some individuals could 
have occurred. However, recreational asbestos use was probably distributed equally 
and this potential misclassification would be low-scale and it would not affect the 
main conclusions of the thesis. 
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4.8.2. ISOLATED PARISHES OUTSIDE THE ´´HOTSPOT´´ 
A high cumulative incidence and relative risk of MM was observed in isolated 
parishes in the Region of North Denmark, outside the 10km radius from asbestos 
industry. All these parishes form no hotspot and have one or two MM cases that 
developed in a small population (N<900). Hence, no statistically significant 
conclusions can be drawn from this observation. Retrospectively, we acknowledge 
that the use of Bayesian smoothing should have been considered, as it could possibly 
have been able to smear out these singular cases. However, a ´´hotspot´´ around the 
city of Aalborg would still be evident and thereby, the main conclusion would not 
have been altered. 
 
4.8.3. RARE CAUSES OF MALIGNANT MESOTHELIOMA 
It was not possible to investigate the population of Study II for rare causes of MM, 
such as exposure to erionite, radiation and genetic susceptibility. Erionite is not 
encountered in the Region of  North Denmark and therefore, we are confident that this 
is not a source of bias for the present cohort. Radiation and heredity are both rare 
causes, which have not been reported in the Region of North Denmark to our 
knowledge, but we cannot rule out that there could be single cases. In total, the 
information sources used in Study II are of high-quality, without recall bias, but from 
compulsory and validated registries, and the MM diagnosis for all the patients was 
confirmed. Hence, the main findings and conclusions are substantiated.  
 
4.8.4. INTERPRETATION OF THE GENETIC TESTING 
A conservative approach of the genetic testing in Study III was chosen and only 
pathogenic or likely pathogenic inherited mutations were investigated. Similarly, the 
panels used to detect acquired mutations did not include all the genes that are involved 
in the HR DNA pathway. Furthermore, both the platforms that were utilized may be 
unable to spot small copy number changes. As a result, there could be more patients 
carrying a pathogenic germline or somatic mutation that were not reported.  
 
4.8.5. SELECTION BIAS 
The men and women that were included in Study III attended a tertiary referral center, 
which encloses referral bias. The population of tertiary-care centers consists mostly 
of younger patients with a good performance status, as elderly and feeble individuals 
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are unlikely to be referred. Besides, the asbestos exposure and the familial history of 
cancer in Study II was self-reported, thus recall bias is possible. However, the finding 
that limited asbestos exposure and family history of malignancy are associated with 
higher odds of carrying a germline mutation is concordant with previous and 
subsequent studies. 
 
4.8.6. DIRECT EVIDENCE OF CAUSATION 
There was available tissue for sequencing from only five of the patients with germline 
mutations. This limitation did not allow us to perform further functional tests on tumor 
specimens in order to support the causation of MM genesis. In addition, all the 
patients, whose families presented with more than one MM cases, carried a germline 
BAP1 mutation. Our hypothesis that germline mutations in BRCA2, CDKN2A, 
TMEM127, VHL and WT1 have a causal relation with MM pathogenesis would be 
further supported if one or more of those genes were found to be mutated in familial 
MM cases. 
 
4.9. CONCLUSION 
This thesis reaches notable conclusions regarding risk factors for MM. Historically, 
MM was mainly attributed to occupational exposure to asbestos, but Study II 
demonstrates that non-occupational exposure seems to be the primary cause of MM 
for women and may be implicated in MM tumorigenesis for the majority of the men. 
A ´´hotspot´´ within 10km of asbestos plants stands out, where the highest cumulative 
incidence and relative risk of MM for women and men is noticed. Interestingly, the 
male and female MM patients have significantly different exposure patterns, but 
combined exposures (e.g. occupational and environmental or domestic and 
environmental), which are rarely documented, are common for both populations. 
Study III highlights that germline mutations are probably involved in MM 
susceptibility at a higher degree than was previously believed. Inherited mutations in 
13 cancer susceptibility genes were identified for 12% of a MM population. Six of 
these genes are overrepresented among MM patients in comparison to a non-cancer 
population, which supports their causative role in MM carcinogenesis. Furthermore, 
Study III describes limited asbestos exposure, peritoneal disease, history of additional 
primary malignancies and early-onset MM diagnosis as clinical predictors of a 
germline mutation. In addition, more than half of the mutation carriers have an 
inherited or acquired genetic defect in the HR-mediated DNA repair pathway, which 
may have clinical implications as to potential chemotherapeutic targets. Lastly, this 
thesis outlines the established and emerging MPM biomarkers and underlines the need 
for validated and robust diagnostic, prognostic and predictive biomarkers to assist the 
CHAPTER 4. DISCUSSION 
79 
clinicians. Nonetheless, these studies have also raised some questions and have set the 
foundation for future research. 
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CHAPTER 5. FUTURE PERSPECTIVES 
This thesis has generated new hypotheses to investigate and has provided the 
framework for future studies. The following studies are being planned: 
 
Study 1. Patient characteristics associated with better prognosis, and 
identification of treatment types that increase survival.  
The search of the Danish registries and the medical journals for the population of 
Study II provided us with useful asbestos exposure, pathological and clinical 
information for all the MM patients. The asbestos exposure and pathological 
characteristics are described above under Study II. The clinical information include 
survival, type of treatment, age, gender, performance status, comorbidities and stage 
of MM. A large retrospective study has been conducted to investigate potential 
prognostic factors for men and women with MM. The main focus of the study is to 
elucidate which patient characteristics are associated with better prognosis, and which 
treatment types increase survival. A manuscript is in progress and expected to be 
submitted in summer 2019. 
 
Study 2. Potential prognostic and predictive MM biomarkers for chemotherapy. 
We have prospectively consented 30 patients with MPM and we have gathered blood 
and tumor tissue samples before treatment for all of them. Some of the patients 
received chemotherapy, others received chemotherapy and underwent surgery, while 
a minority received no treatment. We have also acquired blood samples after therapy, 
at the time of disease progression for most of the inoperable patients, and both blood 
and tumor specimens at the time of surgery for the operable patients. The inclusion of 
patients for Study 2 is completed, but blood/tumor samples after therapy have not 
been gathered from all the patients yet, as some of them are currently under treatment. 
We are planning to test prognostic and predictive biomarkers on the patients´ tumor 
and blood samples and to correlate our findings with the patients´ clinical data and 
course of disease. The promising biomarkers that will be discovered will be validated 
on the retrospective material from Study II. 
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Study 3. Validation of potential prognostic and predictive MM biomarkers for 
chemotherapy. 
After the reclassification of the MM samples of the population of Study II, there was 
available tumor tissue from 180 patients. At the same time, there are clinical and 
pathological data about all these patients at our disposal. Thus, we designed an 
exploratory study to investigate promising predictive and prognostic biomarkers for 
MM. The choice of the biomarkers is based on Study I and emerging research. The 
results of the testing of the biomarkers will be correlated with the patients´ clinical 
data. In order to test several biomarkers simultaneously with the minimal tissue waste, 
we will use tissue microarray (TMA), which has been constructed at the Institute of 
Pathology. We expect that this study will generate several scientific papers. 
 
Study 4. Potential prognostic and predictive MM biomarkers for both 
immunotherapy and chemotherapy. 
A prospective study is ongoing at The University of Chicago Medicine MM clinic, 
aiming to examine prognostic and predictive MM biomarkers for immunotherapy. 
The study is currently including patients. Both tumor tissue samples before 
immunotherapy and detailed clinical information for all the patients will be available. 
We are planning to use the same panel of prognostic and predictive biomarkers in this 
study and the above-described Study 2 and combine the findings of the two groups in 
order to investigate potential prognostic and predictive MM biomarkers for both 
immunotherapy and chemotherapy. 
 
Study 5. The landscape of genetic susceptibility of asbestos induced MM in 
Denmark and abroad.  
Blood samples of Danish MM patients as well as blood specimens from biobanks 
abroad will be sequenced to identify the spectrum of cancer susceptibility genes. This 
is a collaborative multicenter effort, including Aalborg University Hospital, Århus 
University Hospital and The University of Chicago MM clinic, which is currently 
being organized. 
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Appendix A. BACKGROUND 
Table 1. Represents the cases, crude rate and age/standardized rate for Malignant Pleural 
Mesothelioma (MPM) in Denmark (DK) and in the Region of North Denmark (ND) during 
1972-2015 (data from NORDCAN). 
Years MPM 
cases 
in DK 
Crude 
rate for 
DK 
Age-
standardized 
rate in DK 
MPM 
cases in 
ND 
Crude 
rate in 
ND 
Age-
standardized 
rate in ND 
1972 42 1.7 2.2 4 1.4 1.6 
1973 45 1.8 2.4 4 1.4 1.6 
1974 36 1.4 1.8 3 1.1 1.0 
1975 46 1.8 2.3 5 1.8 2.1 
1976 26 1.0 1.2 4 1.4 1.4 
1977 42 1.7 2.1 4 1.4 1.6 
1978 40 1.6 2.0 3 1.1 1.2 
1979 43 1.7 2.2 2 0.7 1.2 
1980 55 2.2 2.8 10 3.5 4.1 
1981 52 2.1 2.6 6 2.1 2.4 
1982 41 1.6 1.9 6 2.1 2.2 
1983 61 2.4 3.0 7 2.5 2.7 
1984 54 2.1 2.5 2 0.7 0.9 
1985 48 1.9 2.3 7 2.5 2.6 
1986 64 2.5 3.1 9 3.2 3.2 
1987 43 1.7 2.0 7 2.5 2.5 
1988 60 2.4 2.8 13 4.6 5.2 
1989 63 2.5 3.0 10 3.5 3.9 
1990 48 1.9 2.3 6 2.1 2.5 
1991 46 1.8 2.1 10 3.5 3.9 
1992 67 2.6 3.2 9 3.1 3.6 
1993 65 2.5 3.1 10 3.5 3.8 
1994 58 2.3 2.7 7 2.4 3.0 
1995 69 2.7 3.1 7 2.4 2.5 
1996 63 2.4 2.8 15 5.2 5.6 
1997 88 3.4 3.8 17 5.9 6.1 
1998 67 2.6 2.9 9 3.1 3.6 
1999 91 3.5 3.8 20 6.9 7.2 
2000 65 2.5 2.9 10 3.4 4.2 
2001 81 3.1 3.5 15 5.2 5.3 
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2002 73 2.7 3.1 15 5.2 5.1 
2003 69 2.6 2.7 10 3.4 3.3 
2004 72 2.7 2.9 14 4.8 5.1 
2005 80 3.0 3.2 18 6.2 6.1 
2006 90 3.3 3.5 21 7.2 7.0 
2007 93 3.4 3.6 14 4.8 4.4 
2008 84 3.1 3.1 18 6.2 5.9 
2009 97 3.5 3.6 14 4.8 4.7 
2010 98 3.6 3.9 19 6.5 6.5 
2011 107 3.9 3.9 24 8.2 7.3 
2012 99 3.6 3.4 14 4.8 4.3 
2013 93 3.3 3.3 18 6.2 5.2 
2014 100 3.6 3.6 10 3.4 3.2 
2015 112 3.9 3.8 23 7.8 6.6 
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Appendix B. STUDY II 
Table 1a. Parishes in the Region of  North Denmark with MM cases (all types of asbestos 
exposure) in 1974-2015 for women. 
Parish MM 
cases 
(N) 
Female 
residents        
(N, median) 
Cases per 
100,000 
residents (N) 
RR for MM 
Parish/ 
Denmark 
95% CI 
1 11 3721 296 10.5 5.5, 19.4 
2 7 6381 110 3.9 1.7, 8.4 
3 5 4048 124 4.4 1.6, 10.9 
4 5 3026 165 5.9 2.2, 14.5 
5 4 3522 114 4.0 1.3, 11.1 
6 4 4372 92 3.2 1.0, 8.9 
7 4 6243 64 2.3 0.7, 6.3 
8 3 2643 114 4.0 1.0, 12.8 
9 2 6132 33 1.2 0.2, 3.7 
10 2 3004 67 2.4 0.4, 9.5 
11 2 4808 42 1.5 0.3, 5.9 
12 2 1651 121 4.3 0.7, 17.3 
13 2 1524 131 4.7 0.8, 18.7 
14 2 3277 61 2.2 0.4, 8.7 
15 2 4639 43 1.5 0.3, 6.2 
16 2 2486 81 2.9 0.5, 11.5 
17 1 4496 22 0.8 0.04, 5.1 
18 1 1302 77 2.7 0.1, 17.7 
19 1 483 207 7.4 0.4, 47.4 
20 1 184 544 19.3 1.0, 122.6 
21 1 574 174 6.2 0.3, 39.9 
22 1 221 453 16.0 0.8, 102.4 
23 1 2005 50 1.8 0.1, 11.5 
24 1 163 614 21.8 1.1, 138.0 
25 1 4122 24 0.9 0.05, 5.6 
26 1 1746 57 2.0 0.1, 13.2 
27 1 2981 34 1.2 0.1, 7.7 
28 1 2088 48 1.7 0.1, 11.0 
29 1 3405 29 1.0 0.1, 6.8 
30 1 386 259 9.2 0.5, 59.1 
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31 1 413 242 8.6 0.5, 55.2 
32 1 838 119 4.2 0.2, 27.4 
33 1 3253 31 1.1 0.1, 7.1 
34 1 5157 19 0.7 0.04, 4.5 
35 1 91 1105 39.2 2.0, 243.8 
36 1 1154 87 3.1 0.2, 20 
37 1 1794 56 2 0.1, 12.8 
38 1 257 390 13.8 0.7, 88.5 
39 1 1573 64 2.3 0.1, 14.6 
40 1 1862 54 1.9 0.1, 12.4 
41 1 2335 43 1.5 0.1, 10 
42 1 1654 61 2.1 0.1, 14 
43 1 2506 40 1.4 0.1, 9.2 
44 1 4007 25 0.9 0.04, 5.7 
 
 
Table 1b. Parishes in the Region of North Denmark with MM cases (exclusively environmental 
asbestos exposure) in 1974-2015 for women. 
Parish MM cases 
(N) 
Female 
residents  
(N, median) 
Cases per 
100,000 
residents (N) 
RR for MM 
Parish/ 
Denmark 
95% CI 
1 3 3721 80.6 2.9 0.7, 9.1 
2 4 6381 62.7 2.2 0.7, 6.1 
3 1 4048 24.7 0.9 0.04, 5.7 
4 3 3026 99.2 3.5 0.9, 11.2 
5 1 3522 28.4 1.0 0.1, 6.5 
6 3 4372 68.6 2.4 0.6, 7.8 
10 1 3004 33.3 1.2 0.1, 7.7 
13 1 1524 65.6 2.3 0.1, 15.1 
29 1 3405 29.4 1.0 0.1, 6.8 
33 1 3253 30.7 1.1 0.1, 7.1 
41 1 2335 42.8 1.5 0.1, 9.9 
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Table 2a. Parishes in the Region of North Denmark with MM cases (non-occupational asbestos 
exposure) in 1970-2015 for men. 
Parish 
number 
MM cases 
(N) 
Male residents 
(N, median) 
Cumulative incidence per 
100,000 person-years 
95% CI 
2 7 6294 2.42 1.19, 5.86 
3 5 3609 3.01 1.24, 8.37 
5 3 3186 2.05 0.59, 7.31 
6 3 4273 1.53 0.44, 5.45 
301 3 2477 2.63 0.76, 9.40 
1 2 3588 1.21 0.24, 5.48 
10 2 2971 1.46 0.29, 6.61 
250 2 272 15.98 3.11, 71.22 
141 2 3436 1.27 0.25, 5.72 
27 2 2844 1.53 0.30, 6.91 
33 2 3000 1.45 0.28, 6.55 
17 1 4399 0.49 0.03, 3.60 
12 1 1709 1.27 0.08, 9.25 
40 1 1738 1.25 0.07, 9.10 
61 1 3666 0.59 0.03, 4.32 
29 1 3278 0.66 0.04, 4.83 
15 1 4486 0.48 0.03, 3.53 
41 1 2315 0.94 0.06, 6.83 
9 1 5644,5 0.39 0.02, 2.80 
14 1 3132 0.69 0.04, 5.05 
7 1 6319 0.34 0.02, 2.50 
21 1 594,5 3.66 0.21, 26.47 
154 1 626 3.47 0.20, 25.14 
99 1 1225 1.77 0.10, 12.89 
26 1 1675 1.30 0.08, 9.43 
161 1 88 24.70 1.45, 172.06 
172 1 337 6.45 0.38, 46.45 
239 1 311 7.00 0.41, 50.36 
266 1 5396 0.40 0.02, 2.93 
316 1 1511 1.44 0.09, 10.46 
332 1 454 4.79 0.28, 34.62 
349 1 244 8.91 0.22, 63.86 
44 1 3721 0.58 0.03, 4.25 
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Table 2b. Parishes in the Region of North Denmark with MM cases (occupational asbestos 
exposure) in 1970-2015 for men. 
Parish 
number 
MM cases 
(N) 
Male residents    
(N, median) 
Cumulative incidence 
per 100,000 person years 
95% CI 
2 22 6294 7.60 5.48, 13.13 
3 20 3609 12.05 8.49, 21.25 
130 16 4991 6.97 4.63, 12.99 
17 12 4399 5.93 3.61, 11.97 
1 11 3588 6.67 3.93, 13.81 
5 10 3186 6.82 3.89, 14.56 
10 8 2971 5.85 3.06, 13.48 
6 8 4273 4.07 2.12, 9.38 
12 8 1709 10.18 5.31, 23.41 
40 8 1738 10.01 5.22, 23.01 
61 7 3666 4.15 2.04, 10.05 
29 6 3278 3.98 1.81, 10.23 
15 6 4486 2.91 1.33, 7.48 
41 6 2315 5.63 2.57, 14.48 
4 6 2872 4.54 2.07, 11.68 
119 5 862 12.62 5.22, 34.92 
8 5 2525 4.30 1.78, 11.96 
25 4 3949 2.20 0.79, 6.79 
301 4 2477 3.51 1.26, 10.81 
9 3 5645 1.16 0.33, 4.13 
24 3 181 36.13 10.49, 
126.07 
14 3 3132 2.08 0.60, 7.44 
250 3 272 23.98 6.96, 84.35 
306 3 5428 1.20 0.355, 4.29 
43 3 2438 2.68 0.78, 9.55 
60 2 591 7.36 1.43, 33.08 
75 2 669 6.50 1.26, 29.22 
90 2 1956 2.22 0.43, 10.04 
141 2 3436 1.27 0.25, 5.72 
11 2 46376 0.94 0.18, 4.24 
209 2 16345 2.66 0.52, 12.01 
7 2 63195 0.69 0.13, 3.11 
215 2 39865 1.09 0.21, 4.93 
13 2 20295 2.14 0.42, 9.68 
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295 2 3210 1.35 0.26, 6.12 
49 1 11085 1.96 0.11, 14.25 
18 1 1211 1.80 0.10, 13.04 
63 1 1813 1.20 0.07, 8.72 
65 1 9385 2.32 0.14, 16.82 
66 1 374 5.81 0.34, 41.90 
21 1 5955 3.66 0.21, 26.47 
73 1 15185 1.43 0.08, 10.41 
79 1 2485 0.87 0.051, 6.37 
103 1 602 3.61 0.21, 26.16 
109 1 628 3.46 0.20, 25.06 
123 1 389 5.59 0.33, 40.30 
134 1 429 5.07 0.30, 36.62 
154 1 626 3.47 0.20, 25.14 
155 1 223 9.77 0.57, 69.92 
156 1 1443 1.51 0.09, 10.95 
27 1 2844 0.76 0.04, 5.56 
167 1 3214 0.68 0.04, 4.92 
192 1 560 3.89 0.23, 28.11 
31 1 458 4.75 0.28,34.29 
255 1 355 6.12 0.36, 44.12 
33 1 3000 0.72 0.04, 5.27 
284 1 928 2.34 0.14, 17 
296 1 209 10.40 0.61, 74.35 
36 1 1183 1.84 0.11, 13.35 
299 1 2171 1.00 0.06, 7.28 
37 1 1854 1.17 0.07, 8.53 
321 1 290 7.50 0.44, 53.87 
324 1 787 2.76 0.16, 20.03 
325 1 780,5 2.79 0.16, 20.19 
331 1 726 3.00 0.18, 21.71 
31 1 458 4.75 0.28, 34.29 
36 1 1183 1.84 0.11, 13.35 
 
 
RISK FACTORS AND BIOMARKERS FOR MALIGNANT MESOTHELIOMA 
108
 
Appendix C. STUDY III 
Table 1.  Genes (N=147) screened in fresh frozen paraffin embedded tumors by The 
University of Chicago Medicine OncoPlus, a custom targeted genomic capture and 
next generation sequencing assay 
ABL
1 
ATM ALK APC ARID
1A 
ARI
D2 
ASXL
1 
ATM ATR ATRX 
AXL B2M BAP1 BCOR BCO
RL1 
BIR
C3 
BLM BRA
F 
BRCA1 BRCA
2 
BTK CALR CBL CBLB CCN
D1 
CCN
D2 
CCN
D 
CDH
1 
CDKN2
A 
CEBP
A 
CHE
K1 
CHE
K2 
CSF1
R 
CSF3
R 
CTC
F 
CTN
NA1 
CTN
NB1 
CUX
1 
CXCR4 DAXX 
DDR
2 
DDX3
X 
DDX4
1 
DICE
R1 
DNM
T3A 
EGF
R 
EP30
0 
EPH
A3 
EPHA5 ERBB
2 
ERB
B3 
ERBB
4 
ERCC
3 
ESR1 ETV6 EZH
2 
FAN
CA 
FAT3 FBXW7 FGFR
1 
FGF
R2 
FGFR
3 
FH FLT3 FOX
L2 
GAT
A1 
GAT
A2 
GNA
11 
GNAQ GNAS 
GRI
N2A 
H3F3
A 
HIST1
H3B 
HIST1
H3C 
HNF
1A 
HRA
S 
IDH1 IDH2 IKZF1 ITPK
B 
JAK
2 
KDM
6A 
KDR KIT KMT
2A 
KRA
S 
MAP
2K1 
MAP
K1 
MET MLH1 
ML
H3 
MPL MRE1
1A 
MSH2 MSH
6 
MTO
R 
MYD
88 
NBN NF1 NF2 
NFE
2L2 
NOTC
H1 
NOTC
H2 
NPM1 NRA
S 
PAL
B2 
PBR
M1 
PDG
FRA 
PDGFR
B 
PHF6 
PIK
3CA 
PIK3
CB 
PIK3
R1 
PLCG
2 
POL
E 
POT
1 
PPP2
R1A 
PTC
H 
PTEN PTPN
11 
RAD
21 
RAD5
1 
RB1 RET RUN
X1 
SDH
B 
SDH
C 
SDH
D 
SETBP1 SF3B
1 
SMA
D4 
SMAR
CB1 
SMC1
A 
SMC3 SMO SFS
R2 
STAG
2 
STK1
1 
TERT 
(promot
er) 
TET2 
TP5
3 
TSC1 TSC2 U2AF
1 
VHL WT1 ZRSR
2 
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Table 2. Detailed clinical characteristics of patients with malignant mesothelioma and 
a germline cancer predisposition mutation. 
P
at
ie
nt 
 
I
D 
Sex Age at 
Diagno
sis 
Site 
of 
Origi
n 
Histo
logy 
Second 
Cancer  
 
Cancer 
in FDR 
or SDR 
*Fulfil
led 
criteria 
for 
genetic 
testing 
Asbesto
s 
Exposu
re 
Germli
ne 
Gene 
Mutate
d 
Acq
uire
d 
mut
atio
n(s)  
Moderate to high penetrance risk alleles 
U
C
1
7
0 
Fem
ale 
57 Perit
oneu
m 
Epith
elioi
d 
Breast Uterus, 
Lung, 
Colore
ctal, 
Prostat
e 
Family 
history 
meets 
Lynch 
syndro
me 
criteria 
None ATM BAP1 
(p.Val2
47fs*2) 
U
C
2
5
8 
Mal
e 
59 Pleur
a 
Epith
elioi
d 
None Lung, 
Breast, 
Basal 
cell 
skin 
cancer 
Person
al + 
family 
history 
meet 
BAP1 
criteria 
Definit
e / 
Primary 
ATM NA 
U
C
0
4
1 
Mal
e 
37 Perit
oneu
m 
Epith
elioi
d 
None Leuke
mia 
No Probabl
e / 
Second
ary 
BAP1 BAP1 
(c.68-
2A>C 
in 
trans) 
BAP1 
loss by 
IHC 
U
C
1
0
2 
Mal
e 
65 Perit
oneu
m 
Epith
elioi
d 
None Ovaria
n, 
Lung 
(3), 
Urinar
y tract 
Family 
history 
meets 
HBOC 
criteria 
Definit
e / 
Primary 
BAP1 BAP1 
(c.437
+2T>A
) 
CSF1R 
(p.Leu
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756fs*
23) 
U
C
0
6
0 
Mal
e 
61 Perit
oneu
m 
Epith
elioi
d 
None Breast, 
Lymph
oma, 
Lung, 
MM, 
Hepati
c, 
Uterus 
Person
al + 
family 
history 
meet 
BAP1 
criteria 
& 
family 
history 
meets 
HBOC 
criteria 
Definit
e / 
Primary 
BAP1 NA 
BAP1 
loss by 
IHC 
U
C
0
4
9 
Mal
e 
61 Pleur
a and 
perit
oneu
m 
Unk
now
n 
Melano
ma 
MM(2)
, 
Renal(
2), 
Basal 
cell 
skin 
cancer 
Person
al + 
family 
history 
meet 
BAP1 
criteria 
Possibl
e / 
Second
ary 
BAP1 NA 
U
C
2
2
1 
Fem
ale 
55 Perit
oneu
m 
Epith
elioi
d 
None MM Person
al + 
family 
history 
meet 
BAP1 
criteria 
None BAP1 NA 
U
C
2
3
8 
Fem
ale 
74 Perit
oneu
m 
Epith
elioi
d 
Breast Colore
ctal 
Person
al 
history 
meets 
HBOC 
criteria 
None BAP1 NA 
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U
C
2
6
4 
Mal
e 
75 Pleur
a 
Epith
elioi
d 
None Lung, 
Liver 
No Probabl
e / 
Primary 
BRCA
1 
NA 
U
C
1
6
9 
Mal
e 
65 Pleur
a 
Epith
elioi
d 
None Pancre
as, 
Breast, 
Melano
ma 
Person
al + 
family 
history 
meet 
BAP1 
criteria 
Probabl
e / 
Second
ary 
BRCA
2 
NA 
U
C
1
9
1 
Fem
ale 
72 Pleur
a 
Epith
elioi
d 
None Breast Family 
history 
meets 
HBOC 
criteria 
None BRCA
2 
NA 
U
C
2
4
1 
Fem
ale 
56 Perit
oneu
m 
Epith
elioi
d 
None Breast No None BRCA
2 
NA 
U
C
0
6
1 
Fem
ale 
32 Perit
oneu
m 
Epith
elioi
d 
Melano
ma 
Breast(
2), 
Pancre
as, 
Colore
ctal 
(3), 
Lung, 
Lymph
oma 
Family 
history 
meets 
HBOC 
criteria
**  &  
Person
al 
history 
meets 
BAP1 
criteria 
Possibl
e / 
Primary 
& 
Second
ary 
CDKN
2A 
NA 
U
C
2
Mal
e 
64 Pleur
a 
Epith
elioi
d 
None Head 
& 
Neck, 
Colore
ctal, 
No None CDKN
2A 
NA 
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6
5 
Esopha
geal 
U
C
0
1
6 
Mal
e 
61 Pleur
a 
Epith
elioi
d 
None Lymph
oma, 
Colore
ctal 
No Probabl
e / 
Primary 
& 
Second
ary 
CHEK
2 
None 
BAP1 
loss by 
IHC 
U
C
0
6
4 
Mal
e 
62 Pleur
a 
Epith
elioi
d 
None Lymph
oma 
No Definit
e / 
Primary 
CHEK
2 
NA 
U
C
1
2
9 
Mal
e 
76 Perit
oneu
m 
Epith
elioi
d 
Colore
ctal, 
prostat
e 
None No Definit
e / 
Primary 
CHEK
2 
NA 
U
C
2
0
1 
Mal
e 
66 Pleur
a 
Biph
asic 
None Unkno
wn 
No Definit
e / 
Primary 
MRE1
1A 
NA 
U
C
0
8
1 
Mal
e 
56 Pleur
a 
Epith
elioi
d 
None Melano
ma (2), 
Lung, 
Colore
ctal 
Person
al + 
family 
history 
meet 
BAP1 
criteria 
Definit
e / 
Primary 
& 
Second
ary 
MSH6 MSI 
stable 
MMR 
protein
s all 
intact 
by IHC 
U
C
2
4
2 
Fem
ale 
71 Perit
oneu
m 
Epith
elioi
d 
Breast, 
ovarian
, GIST 
Lung, 
Breast 
(2) 
Person
al 
history 
meets 
HBOC 
criteria
*** 
Possibl
e / 
Second
ary 
SDHA NA 
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U
C
0
4
9 
Mal
e 
61 Pleur
a and 
perit
oneu
m 
Unk
now
n 
Melano
ma 
MM(2)
, 
Renal(
2), 
Basal 
cell 
skin 
cancer 
Person
al + 
family 
history 
meet 
BAP1 
criteria 
Possibl
e / 
Second
ary 
TMEM
127 
NA 
U
C
1
2
4 
Fem
ale 
27 Pleur
a 
Epith
elioi
d 
None Prostat
e (4), 
Gastric 
No^ None TP53 NA 
U
C
2
4
0 
Fem
ale 
78 Pleur
a 
Epith
elioi
d 
None Prostat
e, 
Hepati
c 
No None VHL NA 
U
C
0
5
9 
Mal
e 
37 Perit
oneu
m 
Epith
elioi
d 
Wilm's 
tumor 
Colore
ctal, 
Lung 
(2), 
Brain 
No***
* 
None WT1 BAP1 
(p.Lys
425fs*
5) 
Compl
ex 
karyoty
pe on 
tumor 
cytoge
netics 
Low penetrance risk alleles 
U
C
1
3
9 
Fem
ale 
57 Pleur
a 
Epith
elioi
d 
None Lung, 
Breast(
2) 
No None APC NA 
U
C
2
Fem
ale 
66 Pleur
a 
Biph
asic 
None Breast 
(2) 
Family 
history 
meets 
Definit
e / 
APC NA 
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3
0 
HBOC 
criteria 
Second
ary 
U
C
1
0
2 
Mal
e 
65 Perit
oneu
m 
Epith
elioi
d 
None Ovaria
n, 
Lung 
(3), 
Urinar
y tract 
Family 
history 
meets 
HBOC 
criteria 
Definit
e / 
Primary 
MITF CSF1R 
(p.Leu
756fs*
23) 
BAP1 
(c.437
+2T>A
) 
U
C
1
1
4 
Fem
ale 
60 Pleur
a 
Epith
elioi
d 
None Leuke
mia,  
Multipl
e 
myelo
ma 
No Definit
e / 
Primary 
& 
Second
ary 
MITF NA 
U
C
2
4
9 
Mal
e 
77 Pleur
a 
Epith
elioi
d 
Prostat
e 
Lymph
oma, 
Lung 
No Definit
e / 
Primary 
& 
Second
ary 
MUTY
H 
BAP1 
(p.Gln
684*) 
DDX3
X 
(p.Gln
360*) 
Abbreviations:  FDR=first-degree relative; SDR=second-degree relative;  NA=not available; 
HBOC= hereditary breast and ovarian cancer syndrome; MM=malignant mesothelioma;  
GIST=gastrointestinal stromal tumor; IHC=immunohistochemistry 
*Family history is as obtained at the time of first patient interview.  Clinical criteria for 
germline genetic testing include:  National Comprehensive Cancer Network Genetic/Familial  
High-Risk Assessment: Breast and Ovarian and Colon Cancer guidelines (www.nccn.org) as 
well as BAP1 Tumor Prediposition Syndrome clinical testing recommendations 
(https://www.ncbi.nlm.nih.gov/books/NBK390611/) 
**This patient's family had a known BRCA2 mutation in the family, which UC061 did not carry, 
as well as the CDKN2A mutation identified here  
***This patient had clinical panel based testing for hereditary breast and ovarian cancer genes 
that was negative; this panel did not include SDHA.  
****This patient had subtle hemihypertrophy and proteinuria   
^This patient had prior clinical genetic testing identifying the same TP53 mutation confirmed 
in our study 
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